Compositions or kits for target nucleic acid sequence detection

By designing short nucleic acid probes that do not bind to nucleic acid recombination-related enzymes and including abase sites and non-natural nucleotides in the probes, the problems of excessively long probe length and high internal modification costs in existing RPA methods are solved, achieving efficient and low-cost real-time nucleic acid detection.

CN123125344APending Publication Date: 2026-11-17KANEKA CORP
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202580023916.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-03-27
Filing Date
2025-03-25
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In existing real-time nucleic acid detection methods based on RPA, the long length of nucleic acid probes leads to a high risk of nonspecific amplification, the design freedom of fluorescent and quenching substances is low, and the internal modification cost is high, making it difficult to achieve low-cost detection.

Method used

Nucleic acid probes that do not bind to nucleic acid recombination-related enzymes are designed with a length of less than 28 mers. The probes contain debasing sites, oxidized bases, or native nucleotides. Fluorescent and quenching substances are attached to both ends of the probes. Non-native nucleotides such as LNA or AmNA nucleotides are used to increase the freedom of probe design.

Benefits of technology

It reduces the risk of nonspecific amplification, increases the freedom and sensitivity of probe design, enables low-cost multiplex detection, and maintains the specificity and sensitivity of detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123125344A_ABST
    Figure CN123125344A_ABST
Patent Text Reader

Abstract

This invention addresses nucleic acid probes used in real-time nucleic acid detection based on the RPA method, aiming to shorten probe length and avoid either or both of internal modifications. The invention provides a composition or kit for detecting target nucleic acid sequences, comprising: a nucleic acid probe for detecting a target nucleic acid sequence or its complementary sequence, a first nucleic acid primer, and a second nucleic acid primer. The nucleic acid probe contains one or more abase sites, oxidized bases, or native ribonucleotides, and, in addition to the abase sites, contains a base sequence complementary to a probe-binding region within the target nucleic acid sequence or its complementary sequence. It also contains a fluorescent substance and a quenching substance that bind to the nucleic acid probe, and contains one or more non-native nucleotides, and does not bind to nucleic acid recombination-related enzymes to form a complex. The first nucleic acid primer contains a base sequence complementary to a first primer-binding region located at the 3' end of the target nucleic acid sequence and serves as a substrate for nucleic acid recombination-related enzymes. The second nucleic acid primer contains a base sequence complementary to a second primer-binding region located at the 3' end of the complementary sequence of the target nucleic acid sequence and serves as a substrate for nucleic acid recombination-related enzymes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to nucleic acid probes for detecting target nucleic acid sequences, compositions or kits for detecting target nucleic acid sequences, and methods for detecting target nucleic acid sequences. Background Technology

[0002] Isothermal nucleic acid amplification is a technique that amplifies nucleic acids under isothermal conditions without requiring temperature changes. Unlike polymerase chain reaction (PCR), a representative nucleic acid amplification method, which requires complex temperature control of the amplification reaction, it can amplify nucleic acids very simply, which is its main advantage.

[0003] Various methods have been developed for isothermal nucleic acid amplification, including recombinase polymerase amplification (RPA) and loop-mediated isothermal amplification (LAMP). RPA is characterized by the use of nucleic acid recombination-related enzymes (recombinases and / or auxiliary proteins) in the amplification reaction. In PCR, the template double-stranded nucleic acid is denatured and dissociated, followed by cooling to anneal the nucleic acid primers and template. In contrast, in RPA, the nucleic acid recombination-related enzyme forms a complex with the nucleic acid primers, and the binding of the nucleic acid primers to the template is achieved through the action of the enzyme. Figure 1 RPA (Rapid Amplification) can complete the amplification reaction in about tens of minutes, and is therefore gradually becoming more widespread in the medical field, and is also used for rapid detection of pathogens.

[0004] Methods for real-time nucleic acid detection have also been developed within the PCR method and are widely used as real-time PCR. Similar to PCR, real-time detection methods have also been developed within the RPA method, but as described below, the nucleic acid probes used in PCR and RPA differ in structure.

[0005] In the TaqMan probe method, a real-time PCR technique, nucleic acid probes are used, with a fluorophore at the 5' end and a quencher at the 3' end of the nucleic acid strand. Similar to the annealing of nucleic acid primers, the nucleic acid probe binds to the amplification region of the template through cycles of thermal denaturation and cooling. Subsequently, DNA polymerase extends the nucleic acid strand from the primer along the 3' direction, while the nucleic acid probe bound to it is degraded by the 5' exonuclease activity of the DNA polymerase moving in the 3' direction. This degradation causes the fluorophore bound to the nucleic acid probe to separate from the quencher, resulting in fluorescence. In real-time PCR, the amplification amount of nucleic acid can be determined by measuring the change in fluorescence over time.

[0006] In contrast, the RPA method using recombinant nucleic acid-related enzymes employs nucleic acid probes with a structure different from those used in real-time PCR, typically around 30-60 mere molecules. This is because nucleic acid chains need to be at least 28 mere molecules long to form a complex with the recombinant nucleic acid-related enzyme. However, when the enzyme binds, the nucleic acid probe stretches, causing its ends to become spatially distancing. Therefore, binding fluorescent and quenching agents to the 5' and 3' ends of the probe, respectively, does not result in quenching of the fluorescent agent.

[0007] Therefore, in real-time detection methods based on RPA, the fluorescent and quenching substances are bound not at the ends of the nucleic acid probe, but rather close to each other inside the probe. Because the quenching substances are positioned close together, even if nucleic acid recombination-related enzymes bind to the nucleic acid probe, the fluorescent substances can still be quenched.

[0008] Furthermore, in the nucleic acid probes used in the RPA method, a debasement site mimic is placed between the binding sites of the fluorescent substance and the quencher. When the nucleic acid probe binds to the template, *E. coli* exonuclease III cleaves the nucleic acid probe at this debasement site mimic. As a result, the fluorescent substance separates from the quencher and emits fluorescence. Figure 2 ).

[0009] Existing technical documents

[0010] Patent documents

[0011] Patent Document 1: Japanese Patent Publication No. 2009-502161. Summary of the Invention

[0012] In existing real-time detection methods based on RPA (Recombinant Recombinant Processing Algorithm), primers and nucleic acid probes bind to target double-stranded DNA via recombination-associated enzymes (RAAs) for target amplification and detection. In other words, both primers and nucleic acid probes must be substrates for RPA. For primers and nucleic acid probes to be suitable substrates for RPA, they need to be approximately 30-60 meters in length. However, due to their sequence length, non-specific amplification problems often arise due to dimer formation. This trend is even more pronounced in multiplex systems containing a large number of primers or probes.

[0013] As another issue, in the nucleic acid probes used in existing RPA methods, as mentioned above, the fluorescent and quenching substances are not bound to the two ends, but rather need to be bound to each other close to each other inside the nucleic acid probe. Furthermore, because the placement of the fluorescent and quenching substances is restricted by thymine residues, the design freedom of nucleic acid probes is limited. In addition, internal modification is more expensive than end modification, thus posing a barrier to low-cost detection, for example, in the medical field.

[0014] Therefore, the present invention addresses nucleic acid probes used in real-time nucleic acid detection based on RPA method, with the goal of shortening probe length and avoiding either or both of internal modifications.

[0015] The inventors have discovered that by combining primers, which serve as substrates for nucleic acid recombination-related enzymes, with nucleic acid probes that do not bind to these enzymes in real-time detection using the RPA method, the aforementioned problems of existing methods can be solved. Specifically, during nucleic acid amplification, when primers, serving as substrates for nucleic acid recombination-related enzymes, invade and extend double-stranded nucleic acids, resulting in single-stranded regions, nucleic acid probes that do not bind to these enzymes bind, thereby enabling detection. Figure 3 According to the present invention, since it is not necessary to bind the nucleic acid probe to the target sequence with a nucleic acid recombination-related enzyme, it is possible to design probes with shorter lengths than those used in existing RPA methods, thereby reducing the risk of non-specific amplification due to dimer formation, etc. Furthermore, since fluorescent and quenching substances can be modified at both ends of the probe, the probe design offers high freedom and reduces costs.

[0016] In designing the nucleic acid probes of this invention, probes of approximately 28 mer or less that do not insert into the nucleic acid chain were initially designed. However, in the presence of nucleic acid recombination-related enzymes, the fluorescence intensity increased regardless of amplification. The reason for this is believed to be that while nucleic acid probes of approximately 28 mer or less do not effectively penetrate the nucleic acid chain, they still bind to nucleic acid recombination-related enzymes. This binding causes the nucleic acid probe structure to extend, thus spatially distancing the fluorescent and quenching substances modified at both ends. Further research revealed nucleic acid probes that inhibit binding to nucleic acid recombination-related enzymes by including non-natural nucleotides, thereby completing the invention of a novel real-time detection method in the RPA (Real-Time Perception) method.

[0017] Based on this concept, the inventors have discovered a novel structure for nucleic acid probes and a novel real-time detection method based on this structure. They have found that, compared to existing methods, this method exhibits superior specificity and sensitivity, and can achieve multiplex detection that is difficult to achieve with existing methods. Based on the above insights, the present invention provides the following technical solution.

[0018] (1) A composition or kit for detecting a target nucleic acid sequence, comprising a nucleic acid probe for detecting a target nucleic acid sequence or its complementary sequence, a first nucleic acid primer, and a second nucleic acid primer.

[0019] The nucleic acid probe contains one or more abase sites, oxidized bases, or native ribonucleotides. In addition to the abase sites, it contains a base sequence complementary to the probe-binding region of the target nucleic acid sequence or its complementary sequence. It also contains a fluorescent substance and a quenching substance that bind to the nucleic acid probe, and contains one or more non-native nucleotides. Furthermore, it does not bind to nucleic acid recombination-related enzymes to form a complex.

[0020] The first nucleic acid primer contains a base sequence complementary to the first primer-binding region located at the 3' end of the target nucleic acid sequence, and serves as a substrate for nucleic acid recombination-related enzymes.

[0021] The second nucleic acid primer contains a base sequence complementary to the second primer binding region located at the 3' end of the complementary sequence of the target nucleic acid sequence, and serves as a substrate for nucleic acid recombination-related enzymes.

[0022] (2) The composition or kit according to (1), wherein the composition comprises a fluorescent substance bound to the 5' end or 3' end of the nucleic acid probe and a quenching substance bound to the other end.

[0023] (3) The composition or kit according to (1) or (2), wherein the length of the nucleic acid probe is 10 to 20 bases.

[0024] (4) The composition or kit according to any one of (1) to (3), wherein the non-natural nucleotide is a bridged nucleotide or a 2'-modified nucleotide.

[0025] (5) The composition or kit according to (4), wherein the bridging nucleotide is an LNA nucleotide, an AmNA nucleotide, or a GuNA nucleotide.

[0026] (6) The composition or kit according to (4), wherein the bridging nucleotide comprises LNA nucleotide and AmNA nucleotide, or LNA nucleotide and GuNA nucleotide.

[0027] (7) The composition or kit according to any one of (1) to (6), wherein the probe binding region is located in a gap region in the target nucleic acid sequence, the gap region being a region other than the first primer binding region and a region consisting of a base sequence complementary to the second primer binding region.

[0028] (8) The composition or kit according to (7), wherein the probe binding region is located in the region of the notch region further 5' from the end than the center.

[0029] (9) The composition or kit according to any one of (1) to (8), wherein the probe binding region is located in a gap region in the complementary sequence of the target nucleic acid sequence, the gap region being a region other than the second primer binding region and a region consisting of a base sequence complementary to the first primer binding region.

[0030] (10) The composition or kit according to (9), wherein the probe binding region is located in the region of the notch region further 5' from the end than the center.

[0031] (11) The composition or kit according to any one of (1) to (10), wherein the probe binding region comprises one or more bases located on the 3' end side of the region of the target nucleic acid sequence consisting of a base sequence complementary to the second primer binding region, and

[0032] The region in the target nucleic acid sequence consisting of a base sequence complementary to the binding region of the second primer does not include bases in the probe binding region corresponding to the debasement site of the nucleic acid probe, or bases complementary to the oxidized base or the natural ribonucleotide.

[0033] (12) The composition or kit according to any one of (1) to (11), wherein the region in the target nucleic acid sequence consisting of a base sequence complementary to the binding region of the second primer includes a base in the probe binding region corresponding to the ablation site of the nucleic acid probe, or a base complementary to the oxidized base or native ribonucleotide, and

[0034] The debasement site, the oxidized base, or the natural ribonucleotide of the nucleic acid probe, in the presence of the second nucleic acid primer and in the absence of the target nucleic acid sequence, shall not be cleaved by exonuclease III, ribonuclease H, DNA glycosylase, or endonuclease IV.

[0035] (13) The composition or kit according to (12), wherein, in the probe binding region, the overlapping region comprised of the region consisting of a base sequence complementary to the second primer binding region is less than 85% of the total length of the probe binding region.

[0036] (14) The composition or kit according to (13), wherein, in the probe binding region, the length of the 3' end-side overlapping region located further to the 3' end than the base corresponding to the ablation site of the nucleic acid probe, or the base complementary to the oxidized base or the native ribonucleotide, and consisting of a base sequence complementary to the second primer binding region, is 3 bases or less.

[0037] (15) The composition or kit according to (13) or (14), wherein, in the probe binding region, the length of the 3' end overlap region located further to the 3' end than the base corresponding to the ablation site of the nucleic acid probe, or the base complementary to the oxidized base or the native ribonucleotide, and consisting of a base sequence complementary to the second primer binding region, is 4 to 6 bases, and

[0038] In the probe binding region, the length of the 5' end overlap region located further to the 5' end than the base corresponding to the ablation site of the nucleic acid probe, or the base complementary to the oxidized base or the native ribonucleotide, is less than 4 bases.

[0039] (16) The composition or kit according to any one of (1) to (15), wherein the probe binding region comprises one or more bases located on the 3' end side of the region of the complementary sequence of the target nucleic acid sequence consisting of a base sequence complementary to the first primer binding region, and

[0040] The region formed by the base sequence complementary to the binding region of the first primer in the complementary sequence of the target nucleic acid sequence does not contain the bases in the probe binding region corresponding to the debasement site of the nucleic acid probe, or the bases complementary to the oxidized bases or the natural ribonucleotides.

[0041] (17) The composition or kit according to any one of (1) to (16), wherein the region of the complementary sequence of the target nucleic acid sequence consisting of a base sequence complementary to the binding region of the first primer includes a base in the probe binding region corresponding to the debasement site of the nucleic acid probe, or a base complementary to the oxidized base or the native ribonucleotide, and

[0042] The debasement site, the oxidized base, or the natural ribonucleotide of the nucleic acid probe, in the presence of the first nucleic acid primer and in the absence of a complementary sequence to the target nucleic acid sequence, shall not be cleaved by exonuclease III, ribonuclease H, DNA glycosylase, or endonuclease IV.

[0043] (18) The composition or kit according to (17), wherein, in the probe binding region, the overlapping region comprised of the region consisting of a base sequence complementary to the first primer binding region is less than 85% of the total length of the probe binding region.

[0044] (19) The composition or kit according to (18), wherein, in the probe binding region, the length of the 3' end-side overlapping region located further to the 3' end than the base corresponding to the ablation site of the nucleic acid probe, or the base complementary to the oxidized base or the native ribonucleotide, and consisting of a region composed of a base sequence complementary to the first primer binding region, is 3 bases or less.

[0045] (20) The composition or kit according to (18) or (19), wherein, in the probe binding region, the length of the 3' end overlap region located further to the 3' end than the base corresponding to the ablation site of the nucleic acid probe, or the base complementary to the oxidized base or the native ribonucleotide, and consisting of a base sequence complementary to the first primer binding region, is 4 to 6 bases, and

[0046] In the probe binding region, the length of the 5' end overlap region located further to the 5' end than the base corresponding to the ablation site of the nucleic acid probe, or the base complementary to the oxidized base or the native ribonucleotide, is less than 4 bases.

[0047] (21) The composition or kit according to any one of (1) to (20) is used for isothermal nucleic acid amplification.

[0048] (22) The composition or kit according to (21), wherein the composition further comprises strand substitution DNA polymerase, exonuclease III, ribonuclease H, DNA glycosylation enzyme, endonuclease IV, and / or nucleic acid recombination-related enzyme.

[0049] (23) A composition or kit for multiplex detection, comprising multiple probe / primer sets for detecting multiple different target nucleic acid sequences or their complementary sequences,

[0050] Each probe / primer set comprises, as described in any one of (1) to (22) a nucleic acid probe, a first nucleic acid primer, and a second nucleic acid primer.

[0051] The nucleic acid probes in the plurality of probe / primer sets each contain a fluorescent substance that can be detected at different fluorescence wavelengths.

[0052] (24) The composition or kit according to (23), wherein the different plurality of target nucleic acid sequences are derived from the same or different viruses, viroids, and / or organisms.

[0053] (25) A method for detecting a target nucleic acid sequence in a sample, comprising:

[0054] The amplification process involves amplifying the target nucleic acid sequence and / or its complementary sequence in the sample using any one of (1) to (22), the first nucleic acid primer, and the second nucleic acid primer via a nucleic acid amplification method; and

[0055] The detection process involves irradiating the nucleic acid probe during and / or after the amplification process with excitation light and detecting the fluorescence emitted by the fluorescent substance.

[0056] (26) According to the method described in (25), wherein the nucleic acid amplification method is an isothermal nucleic acid amplification method.

[0057] (27) According to the method of (26), wherein the amplification step is performed using a strand displacement DNA polymerase.

[0058] (28) The method according to (27), wherein the amplification step is performed in the presence of a nucleic acid recombination-related enzyme and exonuclease III, ribonuclease H, DNA glycosylation enzyme, or endonuclease IV.

[0059] (29) The method according to any one of (25) to (27), wherein the target nucleic acid sequence is composed of RNA.

[0060] It further includes a reverse transcription step: the RNA is reverse transcribed before and / or during the amplification step.

[0061] (30) The method according to any one of (25) to (29), wherein the method further comprises an extraction step: extracting nucleic acid containing the target nucleic acid sequence from the sample prior to the amplification step.

[0062] (31) The method according to any one of (25) to (30), wherein the sample is a cell, tissue, cell extract, tissue extract, tissue fluid or body fluid.

[0063] (32) The method according to any one of (25) to (31), wherein the target nucleic acid sequence is derived from a virus, a virusoid, and / or an organism.

[0064] (33) A nucleic acid probe for detecting a target nucleic acid sequence, comprising one or more abase sites, oxidized bases, or native ribonucleotides.

[0065] In addition to the aforementioned abase sites, it includes a base sequence complementary to the probe-binding region within the target nucleic acid sequence or its complementary sequence.

[0066] It contains a fluorescent substance and a quenching substance that bind to the nucleic acid probe, and

[0067] It contains one or more non-natural nucleotides and does not bind to nucleic acid recombination-related enzymes to form a complex.

[0068] (34) The nucleic acid probe according to (33) comprises a fluorescent substance bound to the 5' end or the 3' end of the nucleic acid probe and a quenching substance bound to the other end.

[0069] (35) The nucleic acid probe according to (33) or (34) has a length of 10 to 20 bases.

[0070] (36) The nucleic acid probe according to any one of (33) to (35), wherein the non-natural nucleotide is a bridging nucleotide or a 2'-modified nucleotide.

[0071] (37) The nucleic acid probe according to (36), wherein the bridging nucleotide is LNA nucleotide, AmNA nucleotide, or GuNA nucleotide.

[0072] (38) The nucleic acid probe according to (36), wherein the bridging nucleotide comprises LNA nucleotide and AmNA nucleotide, or LNA nucleotide and GuNA nucleotide.

[0073] This specification contains the disclosure of Japanese Patent Application No. 2024-051145, which forms the basis of the priority claim of this application.

[0074] According to the present invention, for nucleic acid probes used in real-time nucleic acid detection based on RPA method, it is possible to shorten the probe length and / or avoid internal modification. Attached Figure Description

[0075] Figure 1 This is a diagram illustrating the RPA method. In the diagram, "SSB" represents a single-chain binding protein.

[0076] Figure 2 This is a diagram illustrating an overview of existing real-time detection methods based on the RPA approach.

[0077] Figure 3 This is a diagram illustrating an overview of a novel real-time detection method based on the RPA approach.

[0078] Figure 4 This is a diagram illustrating one embodiment of the nucleic acid probe of the present invention.

[0079] Figure 5 This is a diagram illustrating one embodiment of the nucleic acid probe of the present invention.

[0080] Figure 6 This demonstrates the results of real-time detection using reverse primers positioned at various locations relative to the probe. The reverse primers are designed such that their 3' terminal bases correspond to the positions of 0, +1, +3, +5, +10, +20, and +43 bases, based on the position of the base adjacent to the 3' terminal base of the probe (the 3' terminal direction is shown as positive, and the 5' terminal direction as negative).

[0081] Figure 7 This is a graph showing the results of a detailed analysis of the positional relationships between probes and primers that can detect the template nucleic acid. In the table below the graph, for each combination of probe and reverse primer, the length of the 3' end overlap region is represented as "A", the length of the 5' end overlap region is represented as "B", the combination that can detect the target template nucleic acid is represented as "Yes", and the combination that cannot detect it is represented as "No".

[0082] Figure 8 This is a graph showing the results of comparing the specificity of the real-time detection method of the present invention with that of existing real-time detection methods. Figure 8 A in the figure shows the specificity analysis results of S-probe 5 as a probe based on existing methods. Figure 8 B in the figure shows the specificity analysis results of S-probe 1, which is used as the probe of the present invention. The result of the amplification reaction in the presence of template nucleic acid is represented as "template (+)" and the result of the amplification reaction in the absence of template nucleic acid is represented as "template (−)".

[0083] Figure 9 This shows the results of a comparison between the detection limits of the real-time detection method of the present invention and existing real-time detection methods for template DNA. Figure 9 Figure A shows the results of analysis on the detection limit of S-probe 5 against template DNA as a probe based on existing methods. Figure 9 B in the figure shows the results of the analysis of the detection limit of S-probe 1, which is used as the probe of the present invention, against template DNA.

[0084] Figure 10 This shows the results of a comparison between the detection limits of the real-time detection method of the present invention and existing real-time detection methods for template RNA. Figure 10 Figure A shows the results of analysis on the detection limit of S-probe 5 against template RNA as a probe based on existing methods. Figure 10 B in the figure shows the results of the analysis of the detection limit of S-probe 1, which is used as the probe of the present invention, against template RNA.

[0085] Figure 11 This is a graph showing the results of real-time detection based on the RPA method under conditions of various impurities. Figure 11 A in the figure shows the results when human genomic DNA was used as an impurity. Figure 12 B in the figure shows the results using saliva-derived DNA extract as an impurity. The result of the amplification reaction in the presence of template nucleic acid is represented as "template (+)", the result of the amplification reaction in the absence of template nucleic acid is represented as "template (−)", the result of the amplification reaction in the presence of each impurity is represented as "impurity (+)", and the result of the amplification reaction in the absence of impurities is represented as "impurity (−)".

[0086] Figure 12 The results of single-target real-time detection are shown using plasmid DNA sequences derived from Chlamydia trachomatis and the porA gene derived from Neisseria gonorrhoeae. Figure 12 A in the figure shows the detection result of the ORF4 sequence of plasmid DNA derived from Chlamydia trachomatis. Figure 12 B in the figure shows the detection results of the porA gene derived from Neisseria gonorrhoeae.

[0087] Figure 13 The results show the results of multiple real-time detection of each target sequence in the same sample using the ORF4 sequence of plasmid DNA derived from Chlamydia trachomatis and the porA gene derived from Neisseria gonorrhoeae as detection targets. Figure 13 The A in the figure represents the detection result of the porA gene derived from Neisseria gonorrhoeae. Figure 13 B in the diagram shows the detection results of plasmid DNA sequences derived from Chlamydia trachomatis.

[0088] Figure 14 The results show the real-time detection of the S gene of SARS-CoV-2 using three different probes (S-probe 1, S-probe 23, and S-probe 24). Figure 14 A in the diagram shows the detection results when a synthetic DNA fragment consisting of sequence number 13 (200 copies / reaction solution) was used as the template DNA. Figure 14 B in the diagram shows the detection results when a synthetic DNA fragment consisting of sequence number 13 (20 copies / reaction solution) is used as the template DNA.

[0089] Figure 15 The results show the real-time detection using three different probes with the ORF4 sequence of plasmid DNA derived from Chlamydia trachomatis as the detection target. Figure 15 A in the diagram shows the detection results using CTP-probe 1. Figure 15 B in the diagram shows the detection results using CTP-probe 3. Figure 15C in the figure shows the detection results using CTP-probe 4.

[0090] Figure 16 The results show the real-time detection of the porA gene derived from Neisseria gonorrhoeae using three different probes. Figure 16 A in the figure shows the detection results using NG-probe 1. Figure 16 B in the figure shows the detection results using NG-probe 2. Figure 16 C in the figure shows the detection results using NG-probe 3. Detailed Implementation

[0091] 1. Compositions or kits for the detection of target nucleic acid sequences

[0092] 1-1. Overview

[0093] The first aspect of the present invention is a composition or kit for detecting a target nucleic acid sequence. The composition or kit of this aspect includes a nucleic acid probe for detecting a target nucleic acid sequence or its complementary sequence, a first nucleic acid primer, and a second nucleic acid primer. The nucleic acid probe contained in the composition or kit of this aspect is characterized in that it contains one or more non-natural nucleotides and does not bind to nucleic acid recombination-associated enzymes to form a complex.

[0094] 1-2. Definition of Terms

[0095] The following terms, which are frequently used in this specification, are defined.

[0096] The term "nucleic acid amplification method" in this specification refers to a method that uses nucleic acid primers to amplify a specific region of a target nucleic acid using a nucleic acid polymerase. Specific examples of nucleic acid amplification methods include PCR, which is based on a heat denaturation reaction, and isothermal nucleic acid amplification methods such as RPA and LAMP, which are described later.

[0097] The term "isothermal nucleic acid amplification" in this specification refers to nucleic acid amplification methods that can be performed under isothermal conditions. To date, various methods have been developed as isothermal nucleic acid amplification methods. Examples of isothermal nucleic acid amplification methods include recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), exponential amplification reaction (EXPAR), rolling circle amplification (RCA), and isothermal and chimeric primer-initiated amplification of nucleic acids (ICAN). In these isothermal nucleic acid amplification methods, the annealing of the nucleic acid primers with the template and the subsequent extension reaction occur simultaneously in a reaction solution maintained at a constant temperature. For detailed information on various isothermal nucleic acid amplification methods, please refer to Beatriz, BO, Bruno, V and Pedro, VB, (2021) Isothermal Amplification of Nucleic Acids: The Race for the Next “Gold Standard”, Front. Sens., etc.

[0098] "Recombinase polymerase amplification (RPA)" refers to a nucleic acid amplification method characterized by the use of recombinases. In PCR, the double-stranded nucleic acid template is denatured and dissociated by heat, followed by annealing of the nucleic acid primers and template by cooling. In contrast, in RPA, a nucleic acid recombination-related enzyme forms a complex with the nucleic acid primers, and the binding of the nucleic acid primers to the template is achieved through the action of the enzyme. Figure 1 Furthermore, PCR uses thermostable DNA polymerases, while RPA primarily uses strand displacement DNA polymerases. This is because RPA can synthesize DNA while simultaneously dissociating the template double-stranded DNA. PCR typically requires 1-2 hours or more to complete the amplification reaction, while RPA has the advantage of completing the amplification reaction in just tens of minutes.

[0099] In this specification, "real-time detection" refers to the quantification of the degree of nucleic acid synthesis during nucleic acid amplification. For example, a real-time detection method based on PCR is called real-time PCR. Examples of real-time PCR include intercalation methods using reagents that specifically bind to double-stranded DNA (e.g., SYBR Green, TB Green, Eva Green, etc.) and methods using fluorescently labeled probes (e.g., TaqMan probe method and cycling probe method). For example, in the TaqMan probe method, a probe with a quencher at the 5' end and a fluorescent dye at the 3' end is used. Normally, the quencher at the 5' end inhibits the fluorescent dye at the 3' end, but during the extension reaction, the probe is degraded by the 5'→3' exonuclease activity of Taq polymerase, thereby releasing the inhibition of the quencher and emitting fluorescence. The amount of fluorescence reflects the amount of amplified product. Since the cycle number (CT) or time at which the amplified product reaches the detection threshold is inversely correlated with the initial template amount, real-time detection methods can quantify the initial template amount by measuring the CT or time. By measuring CT or time using known templates from several stages and creating a standard curve, the absolute value of the initial template amount for an unknown sample can be calculated.

[0100] Real-time detection methods based on RPA are also known. As mentioned above, in existing methods, nucleic acid probes of about 30-60 meters are used, and fluorescent and quenching substances are usually bound to the bases of the nucleic acid probe other than the ends, typically thymine bases, for detection.

[0101] In principle, the term "nucleic acid chain" in this specification refers to a polymer composed of nucleotides linked together by internucleotide bonds.

[0102] In this specification, "target nucleic acid sequence" refers to the base sequence of the nucleic acid that is the target for detection using nucleic acid probes. The target nucleic acid sequence can be, for example, a target DNA sequence or a target RNA sequence. If it is a target DNA sequence, it can be a genomic DNA sequence, a cDNA sequence obtained by reverse transcription of mRNA, a vector DNA sequence such as a plasmid DNA sequence, etc. Conversely, if it is a target RNA sequence, it can be an mRNA sequence, or a sequence of non-coding RNA such as miRNA, lncRNA, tRNA, or ribozymes.

[0103] In this specification, "nucleic acid probe" (sometimes simply referred to as "probe") refers to a nucleic acid strand that specifically binds to a nucleic acid having a target nucleic acid sequence and is used for detection. Generally, nucleic acid probes primarily composed of DNA are called DNA probes, and nucleic acid probes primarily composed of RNA are called RNA probes. Additionally, nucleic acid probes containing both DNA and RNA are called DNA / RNA hybrid probes.

[0104] In this specification, "nucleic acid primer" (sometimes simply referred to as "primer") means a nucleic acid strand that specifically binds to a portion of a nucleic acid having a target nucleic acid sequence and provides a starting point for polymerase-based nucleic acid synthesis reactions. Nucleic acid primers are typically single-stranded and preferably contain base sequences complementary to a portion of the target nucleic acid sequence that serves as a template for the polymerase reaction.

[0105] In this specification, "probe binding region" refers to the region where a nucleic acid probe binds to the target nucleic acid sequence or its complementary sequence.

[0106] In this specification, "natural base" refers to adenine, cytosine, guanine, thymine, and uracil, as well as any one of the naturally occurring modified bases.

[0107] In this specification, "modified base" refers to any nucleic acid base other than adenine, cytosine, guanine, thymine, or uracil. Examples of modified bases include, but are not limited to, 5-methylcytosine, 5-fluorocytosine, 5-bromocytosine, 5-iodocytosine, N4-methylcytosine, N6-methyladenine, 8-bromoadenine, N2-methylguanine, and 8-bromoguanine.

[0108] In this specification, "debasement site" refers to the site in a nucleotide where a nucleic acid base has been removed. More specifically, it refers to the site at the 1' position of the sugar portion of a nucleotide, such as ribose or deoxyribose, where no nucleic acid base is bound. Debasement sites are also called apurinic / apyrimidinic sites or AP sites. Debasement sites can also be debasement site mimics (also called baseless site mimics). Preferred embodiments of debasement site mimics include tetrahydrofuran residues, d-spacer groups, etc.

[0109] In this specification, "oxidized base" refers to an oxidized native base or modified base. Examples of oxidized native bases include 8-oxoguanine, 2-hydroxyadenine, 8-oxoadenine, fapy-guanine, methyl-fapy-guanine, fapy-adenine, aflatoxin B1-fapy-guanine, 5-hydroxycytosine and 5-hydroxyuracil, 5,6-dihydroxythymidine, thymidine glycol, 5-hydroxy-5-methylhydantoin, uracil glycol, and 6-hydroxy-5,6-dihydrothymidine. Oxidized bases can be removed by DNA glycosylases and become debasement sites. DNA glycosylases include enzymes with only DNA glycosylase activity, as well as enzymes with both DNA glycosylase and AP cleavage enzyme activities. DNA glycosylases with AP cleavage enzyme activity then cleave the debasement sites.

[0110] In this specification, "natural nucleotide" refers to nucleotides that exist in nature. For example, ribonucleotides composed of ribose and bases such as adenine, cytosine, guanine, or uracil can be listed, as well as deoxyribonucleotides composed of deoxyribose and the aforementioned bases such as adenine, cytosine, guanine, or thymine.

[0111] In this specification, "natural ribonucleotides" refers to ribonucleotides that exist in nature. For example, ribonucleotides composed of ribose and bases such as adenine, cytosine, guanine, or uracil can be listed. It should be noted that, in this specification, nucleotides composed of ribose and thymine bases are also included in natural ribonucleotides.

[0112] In this specification, "non-natural nucleotide" refers to any nucleotide other than natural nucleotides, including modified nucleotides and nucleotide analogs. It should be noted that debase sites and oxidized bases are not included in non-natural nucleotides in this specification.

[0113] In this specification, "modified nucleotide" refers to a nucleotide with modifications such as modified bases and / or modified sugar moieties. Examples of modified nucleotides include bridging nucleotides and 2'-modified nucleotides.

[0114] In this specification, "bridged nucleotide" refers to a nucleotide containing a bicyclic sugar moiety. Nucleic acids containing a bicyclic sugar moiety are generally called bridged nucleic acids. A bicyclic sugar can be a sugar whose 2' and 4' carbon atoms are bridged by two or more atoms. Examples of bicyclic sugars are well known to those skilled in the art. Examples of nucleic acids (BNAs) containing bicyclic sugars include, but are not limited to, methyleneoxy(4'-CH2-O-2')BNA (also known as "LNA"), ethoxy(4'-(CH2)2-O-2')BNA (also known as "ENA"), cEtBNA, scpBNA, cMOEBNA, AmNA, and GuNA.

[0115] In this specification, "AmNA" is also called amide-bridged nucleic acid or amide BNA, including the structures R=H, R=Me, R=Et, R=nPr, R=iPr, R=Bn, and R=Phen in (4'-C(O)-N(R)-2')BNA. In the following formula (IV), the structure R=H is called AmNA[NH], the structure R=Me is called AmNA[N-Me], the structure R=Et is called AmNA[N-Et], the structure R=nPr is called AmNA[N-nPr], the structure R=iPr is called AmNA[N-iPr], the structure R=Bn is called AmNA[N-Bn], and the structure R=Phen is called AmNA[N-Phen]. In this specification, AmNA can be any one of AmNA[NH], AmNA[N-Me], AmNA[N-Et], AmNA[N-nPr], AmNA[N-iPr], AmNA[N-Bn] or AmNA[N-Phen], preferably AmNA[N-Me].

[0116]

[0117] [In the formula, R represents a hydrogen atom, methyl, ethyl, n-propyl, isopropyl, benzyl, or phenyl].

[0118] In this specification, "GuNA" refers to guanidine-bridged nucleic acid, also known as guanidine-bridged nucleic acid or guanidine BNA. In the following formula (V), the structure with R=H is called GuNA[NH], the structure with R=Me is called GuNA[N-Me], and the structure with R=t-Bu is called GuNA[Nt-Bu]. GuNA in this specification can be any one of GuNA[NH], GuNA[N-Me], or GuNA[Nt-Bu], preferably GuNA[NH].

[0119]

[0120] [In the formula, R represents a hydrogen atom, methyl or tert-butyl].

[0121] In this specification, "2'-modified nucleotide" refers to a nucleotide containing a 2'-modified sugar. Examples of substituents at the 2' position of a 2'-modified nucleotide include 2'-F (2'-fluorine), -OCH3 (methoxy), -OCH2CH3 (ethoxy), -OCH2NH2 (aminomethoxy), -OCH2CH2NH2 (aminoethoxy), -OCH2CH2F (fluoromethylmethoxy), -OCH2CH2CH2F (fluoromethylethoxy), -CH3 (methyl), -CH2CH3 (ethyl), -CH2CH2CH3 (propyl), -CH2OCH3 (methoxymethyl), -CH2CH2OCH3 (methoxyethyl; MOE), -OCH2OCH3, -OCH2CH2OCH3, -CH2OCH2OCH3, and -CH2OCH2CH2OCH3 (methoxyethoxymethyl; MEM), but are not limited thereto.

[0122] In this specification, "fluorescent material (fluorophore)" refers to a substance that absorbs excitation light of a specific wavelength, is in an excited state, and emits fluorescence when it returns to its original ground state. Examples include fluorescein isothiocyanate (FITC), Texas, Texas Red, Cyanine3, Cyanine5, Cyanine5.5, Cyanine7, Cyanine7.5, carboxyfluorescein (FAM), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), VIC, 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein (JOE), carboxy-X-rhodamine (ROX), tetrachlorofluorescein (TET), Yakima Yellow (registered trademark), Bodipy493, NBD, 6-carboxytetramethylrhodamine (TAMRA), Quasar670, Quasar705, CAL Fluor Red610, SYBR Green, TB Green, Eva Green, and SYTOX. Green, fluorescein or its derivatives, fluorescein or its derivatives, azo compounds, rhodamine or its derivatives, coumarin or its derivatives, pyrene or its derivatives, anthocyanins or their derivatives, etc. These substances can be used alone or in combination of two or more.

[0123] In this specification, "quencher" refers to a substance that has the property of absorbing the excitation energy of the aforementioned fluorescent substances and converting fluorescence into different wavelengths, or the property of inhibiting fluorescence. Examples include TAMRA, 4-(4-dimethylaminophenylazo)benzoic acid (DABCYL), IBRQ, IBFQ, BHQ (registered trademark) 1, BHQ2, or BHQ3. These substances can be used individually or in combination of two or more.

[0124] In this specification, "nucleic acid recombination-related enzyme" refers to an enzyme that acts on two nucleic acid chains and has the activity of directly or indirectly promoting recombination between the two nucleic acid chains. More specifically, "nucleic acid recombination-related enzyme" refers to "recombinase" and / or "helper protein". In this specification, "recombinase" refers to an enzyme that can directly promote the three reaction processes included in the "recombination reaction" described below. In this specification, "helper protein" refers to an enzyme that can directly or indirectly promote one or two reaction processes selected from the three reaction processes included in the "recombination reaction" described below. Nucleic acid recombination-related enzymes can be derived from any organism, virus, or bacteriophage, for example, from eukaryotes such as bacteria, archaea, mammals, and yeast, or bacteriophages. Furthermore, nucleic acid recombination-related enzymes can be mesophilic or thermophilic enzymes. Recombination reactions catalyzed by nucleic acid recombination-related enzymes are known to include homologous recombination and site-specific recombination. Homologous recombination is a recombination reaction between two nucleic acid chains having the same base sequence. Site-specific recombination is a recombination reaction between two nucleic acid chains having the same base sequence but with a specific sequence. In this invention, the nucleic acid recombination-related enzyme is preferably an enzyme that catalyzes homologous recombination. Examples of recombinases that catalyze homologous recombination include RecA protein, T4 uvsX protein, Rad51 protein, and RadA protein. Furthermore, examples of accessory proteins include single-strand-binding proteins (SSBs), T4 uvsY proteins, RecO proteins, RecR proteins, RecF proteins, and RuvA / RuvB complex proteins.

[0125] In this specification, "recombination reaction" refers to a reaction that includes the following processes: the reaction process in which a nucleic acid recombination-related enzyme binds to a nucleic acid strand (e.g., single-stranded DNA) to form a complex; the reaction process in which a nucleic acid recombination-related enzyme searches for a base sequence that is identical to the base sequence of the nucleic acid strand that forms the complex; and the reaction process in which a nucleic acid recombination-related enzyme invades between nucleic acid strands.

[0126] In this specification, the phrase "nucleic acid primers, nucleic acid probes, etc., become substrates of nucleic acid recombination-related enzymes" means that in a recombination reaction catalyzed by nucleic acid recombination-related enzymes, the enzymes can bind to the nucleic acid chains to form complexes and directly or indirectly promote the penetration between nucleic acid chains, or their efficiency is sufficiently high. Furthermore, in this specification, the phrase "nucleic acid primers, nucleic acid probes, etc., do not become substrates of nucleic acid recombination-related enzymes" means that in a recombination reaction catalyzed by nucleic acid recombination-related enzymes, the enzymes do not bind to the nucleic acid chains to form complexes and / or do not penetrate between nucleic acid chains, or their efficiency is sufficiently low. It should be noted that the nucleic acid probes of this invention do not bind to nucleic acid recombination-related enzymes to form complexes, or substantially do not form complexes, or their efficiency is sufficiently low. Whether a specific nucleic acid chain becomes a substrate of a nucleic acid recombination-related enzyme, or whether its efficiency is high or low, can be determined by measuring the recombination activity against that nucleic acid chain and evaluating the binding of the nucleic acid recombination-related enzyme as described in the examples below. For example, nucleic acid chains with fluorescent and quenching substances bound to their 5' and 3' ends, respectively, can be incubated with or without nucleic acid recombination-related enzymes. If the relative fluorescence intensity with or without nucleic acid recombination-related enzymes reaches a certain value (e.g., 2 or higher) compared to the fluorescence intensity without the enzymes, then the nucleic acid chain can be determined to be a substrate for the enzymes.

[0127] In this specification, "single-strand-binding protein (SSB)" refers to any protein capable of binding to single-stranded nucleic acids. By binding to single-stranded nucleic acids, SSBs can prevent the formation of secondary structures, protect them from nuclease digestion, and / or promote nucleic acid replication. Specific examples of SSBs include SSBs derived from *E. coli*, T4gp32, bacteriophage phi29, *Thermus aquaticus*, and hyperthermophilic microorganisms.

[0128] In this specification, "cleavage enzyme" refers to an enzyme that cleaves the nucleic acid probe at the cleavage site described below, relying on the binding of the nucleic acid probe of the present invention to the probe-binding region within the target nucleic acid sequence or its complementary sequence. The type of cleavage enzyme can be appropriately selected according to the type of cleavage site. When the cleavage site is a debasement site, the cleavage enzyme can be exonuclease III or endonuclease IV. Specific examples of exonuclease III include *E. coli* exonuclease III and APE1 protein. Specific examples of endonuclease IV include *E. coli* endonuclease IV (Nfo) and Tth endonuclease IV. When the cleavage site is a native ribonucleotide, the cleavage enzyme can be ribonuclease H. Specific examples of ribonuclease H include *E. coli* ribonuclease H and Tli RNase H. When the cleavage site is an oxidized base, the cleavage enzyme can be a DNA glycosylation enzyme, exonuclease III, and / or endonuclease IV. Oxidized bases are removed by DNA glycosylases, becoming debasement sites. These debasement sites can be cleaved by DNA glycosylases with AP cleavage activity, exonuclease III, and endonuclease IV. Specific examples of DNA glycosylases include Fpg protein, Nth protein, hOGG1 protein, and NTHL1 protein.

[0129] In this specification, "cleavage site" refers to the location where a nucleic acid probe can be cleaved, depending on its binding to a probe-binding region within the target nucleic acid sequence or its complementary sequence.

[0130] In this specification, "strand displacement DNA polymerase" refers to a DNA polymerase that, during the synthesis of a DNA strand complementary to the template DNA, can continue synthesizing the complementary strand while simultaneously dissociating the double helix through base pairing to form a double helix in its extension direction. Furthermore, the process of synthesizing the complementary strand while dissociating the double helix is ​​called a "strand displacement reaction."

[0131] As used in this specification, the term "complementarity" refers to the ability of nucleic acid bases to form so-called Watson-Crick base pairs (natural base pairs) or non-Watson-Crick base pairs (Hoogsteen type base pairs, etc.) through hydrogen bonds. In this invention, a base sequence with at least 80% complementarity, preferably at least 90% (e.g., 95%, 96%, 97%, 98%, or 99% or more), is acceptable. The complementarity of the base sequence can be determined using a BLAST procedure or similar method.

[0132] The term "test" as used in this instruction manual may be replaced with examination, measurement, judgment, or judgment aid. Furthermore, the term "evaluation" as used in this instruction manual is used to include the meaning of aiding diagnosis or evaluation based on test or measurement results.

[0133] The term "test subject" in this specification refers to any living organism, including animals and plants. Animals may include, for example, humans, primates including chimpanzees, pet animals such as dogs and cats, livestock such as cattle, horses, sheep, and goats, rodents such as mice and rats, and mammals such as animals kept in zoos. Humans are the preferred test subject.

[0134] The "sample" used in this specification as the object of detection or evaluation refers to a sample collected or separated from a test subject, a healthy individual, or a group of healthy individuals and used in the detection method of the present invention. Examples include cells, tissues, cell extracts, tissue extracts, tissue fluid, or body fluids, as well as feces, hair, etc. Examples of body fluids include cerebrospinal fluid, interstitial fluid, blood (including serum, plasma, and interstitial fluid), lymph, extracts of various tissues or cells, pleural effusion, sputum, tears, nasal discharge, saliva, urine, etc. Blood can be serum or plasma prepared from blood. Tissues and cells refer, for example, to tissues and cells of a test subject that have or may have a disease (e.g., an infection), and corresponding tissues and cells in a healthy individual. In addition, the sample can also be a biological sample extracted from the above-mentioned samples.

[0135] In this specification, "healthy individual" refers to an individual who does not suffer from a specific disease, preferably an individual who does not suffer from any disease. However, in this specification, healthy cells are also included in the broader sense of a healthy individual. Therefore, any individual who is in a healthy state at either the individual level or the cellular level is referred to as a healthy individual.

[0136] In this specification, "multiple" refers to integers of 2 or more, such as 2 to 10, 2 to 7, 2 to 5, 2 to 4, or 2 to 3 integers.

[0137] In this specification, "homology" of a base sequence refers to the percentage (%) of identical bases in two compared base sequences when gaps are appropriately inserted into one or both sequences as needed to maximize the number of identical bases and then aligned. Homology can be determined using methods known to those skilled in the art, sequence analysis software, etc.

[0138] 1-3. Composition

[0139] The target nucleic acid sequence detection composition or kit of the present invention (hereinafter sometimes referred to as "the composition or kit of the present invention") contains nucleic acid probes and nucleic acid primers as essential components for detecting target nucleic acid sequences or their complementary sequences.

[0140] The number of nucleic acid primers contained in the compositions or kits of the present invention is not limited as long as they are capable of amplifying the target nucleic acid sequence and / or its complementary sequence. However, since a pair of nucleic acid primers is required in principle to amplify the target nucleic acid sequence and / or its complementary sequence, the number of nucleic acid primers is generally two or more, for example, three or more or four or more. In the following description, among the two or more primers contained in the compositions or kits of the present invention, a pair of nucleic acid primers is referred to as the first nucleic acid primer and the second nucleic acid primer.

[0141] The first nucleic acid primer included in the composition or kit of the present invention comprises a base sequence complementary to the target nucleic acid sequence in a manner that binds to the base sequence located at the 3' end. In this specification, the region on the target nucleic acid sequence where the first nucleic acid primer binds is referred to as the "first primer binding region". Furthermore, the second nucleic acid primer included in the composition or kit of the present invention comprises a base sequence complementary to the target nucleic acid sequence in a manner that binds to the base sequence located at the 3' end. In this specification, the region on the target nucleic acid sequence where the second nucleic acid primer binds is referred to as the "second primer binding region". The nucleic acid chain composed of the target nucleic acid sequence and its complementary strand are amplified using the first and second nucleic acid primers.

[0142] The first and second nucleic acid primers contained in the composition or kit of the present invention serve as substrates for nucleic acid recombination-related enzymes.

[0143] The length of nucleic acid primers used as substrates for nucleic acid recombination-related enzymes can be, for example, 12 or more bases, 15 or more bases, 16 or more bases, 17 or more bases, 18 or more bases, 19 or more bases, 20 or more bases, 21 or more bases, 22 or more bases, 23 or more bases, 24 or more bases, 25 or more bases, 27 or more bases, or 30 or more bases. There is no particular upper limit to the length; nucleic acid primers can be, for example, less than 100 bases, less than 90 bases, less than 80 bases, less than 70 bases, less than 60 bases, less than 55 bases, less than 50 bases, less than 45 bases, or less than 40 bases. Examples of such ranges include 25–65 bases or 35–55 bases.

[0144] Furthermore, there are no particular restrictions on the types of nucleotides that constitute the nucleic acid primers, which serve as substrates for nucleic acid recombination-related enzymes. The number of non-natural nucleotides contained in the nucleic acid primers is, for example, 10 or less, 8 or less, 6 or less, or 5 or less, preferably 4 or less, 3 or less, 2 or less, 1 or less, or 0. The first and second nucleic acid primers may also consist of only natural nucleotides, for example, they may consist of only DNA nucleotides.

[0145] The nucleic acid probes (hereinafter sometimes referred to as "nucleic acid probes of the present invention") contained in the compositions or kits of the present invention contain a base sequence complementary to the target nucleic acid sequence or its complementary sequence. It should be noted that when the nucleic acid probe contains more than one abase site as described below, the nucleic acid probe may contain a base sequence complementary to the sequence in the probe-binding region within the target nucleic acid sequence or its complementary sequence after removing the bases corresponding to the abase site of the nucleic acid probe.

[0146] The number of nucleic acid probes contained in the compositions or kits of the present invention is not particularly limited as long as it is 1 or more, for example, it can be 1 or 2, or it can be 2 or more, 3 or more, 4 or more, or 5 or more. There is no particular upper limit, and the number of nucleic acid probes can be, for example, less than 10, less than 9, less than 8, less than 7, or less than 6. For example, the compositions or kits of the present invention may contain nucleic acid probes for detecting target nucleic acid sequences and / or nucleic acid probes for detecting complementary sequences of target nucleic acid sequences.

[0147] The nucleic acid probe of the present invention contains one or more cleavage sites. Specific cleavage sites are selected from debase sites, oxidized bases, and native ribonucleotides. Debase sites are cleaved by exonuclease III or endonuclease IV. Native ribonucleotides are cleaved by ribonuclease H. Oxidized bases are cleaved by DNA glycosylase, exonuclease III, and / or endonuclease IV. The number of cleavage sites in the nucleic acid probe is not limited as long as it is one or more. For example, it can be one or more, two or more, three or more, or four or more, and / or less than 10, less than 9, less than 8, or less than 7; more specifically, it can be one, two, or three. Furthermore, the location of the cleavage sites in the nucleic acid probe is also not limited; the cleavage sites can be located within the nucleic acid probe (nucleotides located at the 5' and 3' ends) and / or at the 5' and / or 3' ends. It should be noted that the cleavage site is in principle composed of any one of the following: a base-degrading site, an oxidized base, or a native ribonucleotide. However, it can also be a combination of any two or three of the following: a base-degrading site, an oxidized base, and a native ribonucleotide.

[0148] The nucleic acid probe of the present invention comprises a fluorescent substance and a quencher substance bound to the nucleic acid probe. The combination of the fluorescent substance and the quencher substance is not particularly limited as long as the quencher substance can absorb the excitation energy of the fluorescent substance and inhibit its fluorescence. The amount of fluorescent substance can be, for example, 1 or more, 2 or more, or 3 or more, and / or 6 or less, 5 or less, or 4 or less; the amount of quencher substance can be, for example, 1 or more, 2 or more, or 3 or more, and / or 6 or less, 5 or less, or 4 or less. The amount of fluorescent substance and quencher substance bound to the nucleic acid probe can be the same or different. For example, the amount of fluorescent substance and quencher substance can be 1, 1 and 2, or 2 and 1 respectively. Furthermore, the binding site of the fluorescent substance and the quencher substance can be inside the nucleic acid probe (any location except the 5' end and 3' end) and / or the 5' end and / or the 3' end. The positional relationship between the fluorescent substance and the quencher substance is not particularly limited as long as one or more cleavage sites are arranged between the fluorescent substance and the quencher substance such that the fluorescent substance separates from the quencher substance after the nucleic acid probe is cleaved at the cleavage site. For example, by placing the fluorescent material at the 5' or 3' end of the nucleic acid probe, placing the quenching material at the other end, and placing the cleavage site at any position other than the 5' and 3' ends, it is possible to avoid introducing the fluorescent material and the quenching material into the nucleic acid probe. Therefore, this method is preferred from the perspective of synthesis cost.

[0149] The nucleic acid probe of the present invention contains one or more non-natural nucleotides and does not bind to nucleic acid recombination-related enzymes to form a complex.

[0150] The types of non-natural nucleotides included in the nucleic acid probe of this invention are not limited as long as they are effective in forming complexes with nucleic acid recombination-related enzymes. In one embodiment, the non-natural nucleotide is a bridging nucleotide or a 2'-modified nucleotide. Bridging nucleotides can be, for example, LNA, ENA, cEtBNA, cMOEBNA, AmNA, or GuNA, preferably LNA, AmNA, or GuNA. Furthermore, bridging nucleotides can be combinations of two or three of LNA, AmNA, and GuNA, for example, a combination of LNA and AmNA or a combination of LNA and GuNA. 2'-Modified nucleotides can be, for example, 2'-methyl modified nucleotides, 2'-MOE modified nucleotides, or 2'-fluorine modified nucleotides. It should be noted that whether the nucleic acid probe becomes a substrate for nucleic acid recombination-related enzymes can be determined as described above by measuring recombination activity or evaluating the binding of nucleic acid recombination-related enzymes.

[0151] The number of non-natural nucleotides contained in the nucleic acid probe of this invention can be 1 or more, without limitation. For example, it can be 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, or 10 or more, and / or less than 60, less than 55, less than 50, less than 45, less than 30, less than 25, less than 20, less than 19, less than 18, less than 17, less than 16, less than 15, less than 14, less than 13, or less than 12.

[0152] The location of non-natural nucleotides in the nucleic acid probes of the present invention is not limited. For example, in the nucleic acid probes of the present invention, fragments of randomly selected or periodically selected lengths (e.g., 1 to 10 bases, 2 to 9 bases, 3 to 8 bases, or 4 to 7 bases) composed of non-natural nucleotides can be alternated with fragments composed of natural nucleotides.

[0153] In addition to non-natural nucleotides, the nucleic acid probes of the present invention may contain natural nucleotides, which may be deoxyribonucleotides or ribonucleotides. For example, the nucleic acid probes of the present invention are composed of non-natural nucleotides and natural deoxyribonucleotides, and do not contain more than 10, 9, 8, 7, 6, 5, 4, 3, or 2 consecutive natural deoxyribonucleotides.

[0154] The length of the nucleic acid probe of the present invention can be, for example, 8 or more bases, 9 or more bases, 10 or more bases, 11 or more bases, 12 or more bases, 13 or more bases, 14 or more bases, or 15 or more bases, and / or less than 30 bases, less than 29 bases, less than 28 bases, less than 27 bases, less than 26 bases, less than 25 bases, less than 24 bases, less than 23 bases, less than 22 bases, less than 21 bases, less than 20 bases, less than 19 bases, less than 18 bases, less than 17 bases, or less than 16 bases. Examples of exemplary ranges include lengths of 8 to 25 bases, 10 to 20 bases, and 12 to 18 bases.

[0155] In one embodiment, the variable L representing the base length of the nucleic acid probe of the present invention and the variable N representing the number of non-natural nucleotides in the nucleic acid probe satisfy the following formulas I and II.

[0156] N≥0.8×L-5.6 (Formula I)

[0157] L > N (Equation II)

[0158] The non-natural nucleotides defined by variable N satisfying Formulas I and II above can be bridging nucleotides and / or 2'-modified nucleotides. Bridging nucleotides can be any of LNA, AmNA, or GuNA, or can include combinations of LNA and AmNA or combinations of LNA and GuNA. Examples of combinations include 2–5 or 3–4 LNAs with 2–5 or 3–4 AmNAs or GuNAs.

[0159] In one embodiment, the non-natural nucleotide defined by the variable N satisfying Formulas I and II above is a bridging nucleotide, which can be any one of LNA, AmNA, or GuNA.

[0160] In one embodiment, the non-natural nucleotide defined by the variable N satisfying Formulas I and II above is a bridging nucleotide, and the bridging nucleotide is LNA. In this embodiment, the number of LNA nucleotides is the variable N satisfying Formulas I and II above, or is less than or equal to the variable N satisfying Formulas I and II above.

[0161] In another embodiment, the non-natural nucleotide defined by variable N satisfying Formulas I and II above is a bridging nucleotide, which includes a combination of LNA and AmNA or a combination of LNA and GuNA. In this embodiment, the total number of LNA and AmNA or the total number of LNA and GuNA is either the variable N satisfying Formulas I and II above, or less than the variable N satisfying Formulas I and II above.

[0162] In yet another embodiment, the nucleic acid probe of the present invention further satisfies the following formula III.

[0163] 10≤L≤20 (Equation III)

[0164] In one embodiment of the composition or kit of the present invention, the probe binding region is located within a gap region in the target nucleic acid sequence. The "gap region" in the target nucleic acid sequence as used in this specification refers to the region in the target nucleic acid sequence excluding the first primer binding region and the region composed of base sequences complementary to the second primer binding region. In this embodiment, the nucleic acid probe of the present invention does not contain a sequence complementary to the second nucleic acid primer.

[0165] In another embodiment of the composition or kit of the present invention, the probe binding region is located in the 5' end region of the gap region of the target nucleic acid sequence, closer to the center than the center. In this specification, "center" in the gap region of the target nucleic acid sequence refers to the position equidistant between the 3' end base of the region formed by the sequence complementary to the second primer binding region and the 5' end base of the first primer binding region (equivalent to the midpoint). In this embodiment, the extension reaction of the second nucleic acid primer can reach the sequence complementary to the probe binding region before the extension reaction of the first nucleic acid primer reaches the probe binding region, thereby making the probe binding region single-stranded. Therefore, the nucleic acid probe of the present invention can bind to the single-stranded probe binding region.

[0166] In one embodiment of the composition or kit of the present invention, the probe binding region is located within a gap region in the complementary sequence of the target nucleic acid sequence. The "gap region" in the complementary sequence of the target nucleic acid sequence, as used herein, refers to the region in the complementary sequence of the target nucleic acid sequence excluding the second primer binding region and the region composed of base sequences complementary to the first primer binding region. In this embodiment, the nucleic acid probe of the present invention does not contain a sequence complementary to the first nucleic acid primer.

[0167] In another embodiment of the composition or kit of the present invention, the probe binding region is located in the 5' end region of the gap region of the complementary sequence of the target nucleic acid sequence, further from the center. In this specification, "center" in the gap region of the complementary sequence of the target nucleic acid sequence refers to the position equidistant (equivalent to the midpoint) between the 3' end base of the region formed by the sequence complementary to the first primer binding region and the 5' end base of the second primer binding region. In this embodiment, the extension reaction of the first nucleic acid primer can reach the sequence complementary to the probe binding region before the extension reaction of the second nucleic acid primer reaches the probe binding region, thereby making the probe binding region single-stranded. Therefore, the nucleic acid probe of the present invention can bind to the single-stranded probe binding region.

[0168] In one embodiment of the composition or kit of the present invention, the probe binding region comprises one or more bases located on the 3' end side of the region in the target nucleic acid sequence composed of base sequences complementary to the second primer binding region, and the region in the target nucleic acid sequence composed of base sequences complementary to the second primer binding region does not contain bases in the probe binding region complementary to the cleavage site of the nucleic acid probe (e.g., bases corresponding to a base debasement sites, oxidized bases, or native ribonucleotides). In this embodiment, the 3' end sequence of the nucleic acid probe of the present invention is complementary to the 3' end sequence of the second nucleic acid primer by one or more bases, but the cleavage site in the nucleic acid probe is not included in the complementary region. Therefore, even assuming that the 3' end sequence of the nucleic acid probe of the present invention binds to the second nucleic acid primer to form a partially double-stranded structure, the cleavage site is not included in the double-stranded structure, and therefore will not be cleaved by binding to the second nucleic acid primer.

[0169] In one embodiment of the composition or kit of the present invention, the region in the target nucleic acid sequence composed of a base sequence complementary to the binding region of the second primer includes a base in the probe binding region complementary to the cleavage site of the nucleic acid probe (e.g., a base corresponding to the abase site, or an oxidized base, or a native ribonucleotide), and the cleavage site of the nucleic acid probe (e.g., a base corresponding to the abase site, or an oxidized base, or a native ribonucleotide) is not cleaved by a cleaving enzyme (e.g., exonuclease III, ribonuclease H, DNA glycosylase, or endonuclease IV) in the presence of the second nucleic acid primer and in the absence of the target nucleic acid sequence. In this embodiment, the 3' end sequence of the nucleic acid probe of the present invention is complementary to the 3' end sequence of the second nucleic acid primer by one or more bases, and the cleavage site in the nucleic acid probe is also included in the complementary region, but it is determined that the cleavage site will not be cleaved by binding to the second nucleic acid primer.

[0170] In another embodiment of the composition or kit of the present invention, the overlapping region in the probe binding region is less than 85% of the total length of the probe binding region (e.g., less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, or less than 10%). The term "overlapping region" in the probe binding region of the target nucleic acid sequence as used in this specification refers to the region in the probe binding region formed by a base sequence complementary to the second primer binding region, i.e., the region overlapping between the probe binding region and the region formed by a base sequence complementary to the second primer binding region.

[0171] In another embodiment of the above-described embodiments, the length of the 3' end overlapping region in the probe-binding region of the target nucleic acid sequence is less than 3 bases (e.g., 3 bases, 2 bases, or 1 base). In this specification, the "3' end overlapping region" in the probe-binding region of the target nucleic acid sequence refers to a region in the probe-binding region located further 3' from the base complementary to the nucleic acid probe cleavage site (e.g., the base corresponding to the debasement site, or an oxidized base, or a native ribonucleotide), and composed of a sequence of bases complementary to the second primer-binding region. Specifically, it refers to the region located further 3' from the base complementary to the cleavage site in the overlapping region between the probe-binding region and the region composed of a sequence of bases complementary to the second primer-binding region.

[0172] In another embodiment of the composition or kit of the present invention, the length of the 3' end overlap region in the probe binding region is 4 to 6 bases (e.g., 4, 5, or 6 bases), and the length of the 5' end overlap region in the probe binding region is less than 4 bases (e.g., 4, 3, 2, or 1 base). In this specification, the "5' end overlap region" in the probe binding region of the target nucleic acid sequence refers to a region in the probe binding region located further 5' from the base complementary to the nucleic acid probe cleavage site (e.g., the base corresponding to the debasement site, or an oxidized base, or a native ribonucleotide), and composed of a sequence of bases complementary to the second primer binding region. Specifically, it refers to a region located further 5' from the base complementary to the cleavage site in the region overlapping the probe binding region and the region composed of a sequence of bases complementary to the second primer binding region.

[0173] In one embodiment of the composition or kit of the present invention, the probe binding region comprises one or more bases on the 3' end side of the region consisting of a base sequence complementary to the first primer binding region in the complementary sequence of the target nucleic acid sequence, and the region consisting of a base sequence complementary to the first primer binding region in the complementary sequence of the target nucleic acid sequence does not contain bases in the probe binding region that are complementary to the nucleic acid probe cleavage site (e.g., a base corresponding to an abase site, an oxidized base, or a native ribonucleotide). In this embodiment, the 3' end sequence of the nucleic acid probe of the present invention is complementary to the 3' end sequence of the first nucleic acid primer by one or more bases, but the cleavage site in the nucleic acid probe is not included in the complementary region. Therefore, even if the nucleic acid probe of the present invention is assumed to form a partially double-stranded structure by binding to the first nucleic acid primer, the cleavage site is not included in the double-stranded structure, and therefore will not be cleaved by binding to the first nucleic acid primer.

[0174] In one embodiment of the composition or kit of the present invention, the region in the complementary sequence of the target nucleic acid sequence consisting of a base sequence complementary to the binding region of the first primer includes a nucleic acid probe cleavage site (e.g., a base corresponding to the abase site, or an oxidized base, or a native ribonucleotide) in the probe binding region, and the cleavage site of the nucleic acid probe (e.g., a base corresponding to the abase site, or an oxidized base, or a native ribonucleotide) is not cleaved by a cleavage enzyme (e.g., exonuclease III, ribonuclease H, DNA glycosylase, or endonuclease IV) in the presence of the first nucleic acid primer and in the absence of a complementary sequence of the target nucleic acid sequence. In this embodiment, the 3' end sequence of the nucleic acid probe of the present invention is complementary to the 3' end sequence of the first nucleic acid primer by one or more bases, and the cleavage site in the nucleic acid probe is also included in the complementary region, but it is determined that the cleavage site will not be cleaved by binding to the first nucleic acid primer.

[0175] In another embodiment of the composition or kit of the present invention, the overlapping region in the probe binding region is less than 85% of the total length of the probe binding region (e.g., less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, or less than 10%). In this specification, the “overlapping region” in the probe binding region of the complementary strand of the target nucleic acid sequence refers to the region in the probe binding region formed by a base sequence complementary to the first primer binding region, i.e., the region overlapping between the probe binding region and the region formed by a base sequence complementary to the first primer binding region.

[0176] In another embodiment of the above-described embodiments, the length of the 3' end overlap region in the probe-binding region of the complementary sequence of the target nucleic acid sequence is less than 3 bases (e.g., 3 bases, 2 bases, or 1 base). In this specification, the "3' end overlap region" in the probe-binding region of the complementary sequence of the target nucleic acid sequence refers to a region in the probe-binding region located further 3' from the base complementary to the nucleic acid probe cleavage site (e.g., the base corresponding to the debasement site, or an oxidized base, or a native ribonucleotide), and composed of a sequence of bases complementary to the first primer-binding region. Specifically, it refers to the region located further 3' from the base complementary to the cleavage site in the overlapping region between the probe-binding region and the region composed of a sequence of bases complementary to the first primer-binding region.

[0177] In another embodiment of the composition or kit of the present invention, the length of the 3' end overlap region in the probe binding region is 4 to 6 bases long (e.g., 4, 5, or 6 bases), and the length of the 5' end overlap region in the probe binding region is less than 4 bases (e.g., 4, 3, 2, or 1 base). In this specification, the "5' end overlap region" in the probe binding region of the complementary sequence of the target nucleic acid sequence refers to a region in the probe binding region located further 5' from the base complementary to the nucleic acid probe cleavage site (e.g., the base corresponding to the debasement site, or an oxidized base, or a native ribonucleotide), and composed of a sequence of bases complementary to the first primer binding region. Specifically, it refers to a region located further 5' from the base complementary to the cleavage site in the region overlapping the probe binding region and the region composed of a sequence of bases complementary to the first primer binding region.

[0178] One embodiment of the composition or kit for detecting target nucleic acid sequences of the present invention is a composition for detecting target nucleic acid sequences (hereinafter sometimes referred to as "the composition of the present invention"). The composition of the present invention may contain any of the above-described nucleic acid probes, a first nucleic acid primer, and a second nucleic acid primer as essential components, and contains solvents and / or additives as selective components. The solvent may be water or an aqueous solution, or it may be an organic solvent. Examples of aqueous solutions include physiological saline, phosphate buffer, sodium acetate buffer, Tris buffer, etc. Furthermore, as additives, examples include chelating agents, pH adjusters, suspending agents, surfactants, stabilizers, excipients, preservatives, diluents, isotropic agents, buffers, solubilizers, etc. In particular, chelating agents such as EDTA and EGTA can inactivate nucleases in the presence of trace amounts, thus stabilizing the nucleic acid probes and primers, which is preferred.

[0179] One embodiment of the composition or kit for detecting target nucleic acid sequences of the present invention is a kit for detecting target nucleic acid sequences (hereinafter sometimes referred to as "the kit of the present invention"). The kit of the present invention comprises, as necessary components, any of the above-described nucleic acid probes, a first nucleic acid primer, and a second nucleic acid primer. In the kit of the present invention, the nucleic acid probes, the first nucleic acid primer, and the second nucleic acid primer can be placed in separate containers, or they can be placed in the same container as in the composition of the present invention described above. Each container may also contain solvents and / or additives as selective components, in addition to the nucleic acid probes, the first nucleic acid primer, and / or the second nucleic acid primer. Furthermore, the kit of the present invention may also include other reagents required for nucleic acid amplification and target nucleic acid detection as selective components, such as strand displacement DNA polymerase, exonuclease III, ribonuclease H, DNA glycosylase, endonuclease IV, nucleic acid recombination-related enzymes, creatine kinase and phosphocreatine, or pyruvate kinase and phosphoenolpyruvate, buffer, dNTPs, ATP, DTT, additives, sample collection equipment, nucleic acid extraction reagents, nucleic acid purification reagents, and / or instructions describing the nucleic acid amplification or target nucleic acid detection method. The kit of the present invention may also be provided as a reagent in the kit.

[0180] In one embodiment, the target nucleic acid sequence detection composition or kit of the present invention can be used in nucleic acid amplification methods such as isothermal nucleic acid amplification. Isothermal nucleic acid amplification and other nucleic acid amplification methods can be quantitative nucleic acid amplification methods, such as real-time detection.

[0181] In one embodiment, the target nucleic acid sequence detection composition or kit of the present invention is a single detection composition or kit. "Single detection" in this specification refers to the use of the target nucleic acid sequence detection composition or kit to detect a single target nucleic acid sequence. In this embodiment, the composition or kit of the present invention comprises the aforementioned first and second nucleic acid primers as a pair of nucleic acid primers for amplifying a single target nucleic acid sequence, and may contain one nucleic acid probe for detecting the target nucleic acid sequence or its complementary sequence, or two or more nucleic acid probes for detecting the target nucleic acid sequence and / or its complementary sequence, each containing a fluorescent substance having a fluorescent wavelength in the same or overlapping wavelength region.

[0182] In another embodiment, the target nucleic acid sequence detection composition or kit of the present invention is a multiplex detection composition or kit. "Multiplex detection" in this specification refers to the detection of individual target nucleic acid sequences from two or more target nucleic acid sequences using the target nucleic acid sequence detection composition or kit. In this embodiment, the composition or kit of the present invention comprises multiple probe / primer sets for detecting multiple different target nucleic acid sequences. Here, each probe / primer set comprises any of the above-described nucleic acid probes, a first nucleic acid primer, and a second nucleic acid primer. Furthermore, the nucleic acid probes in the multiple probe / primer sets each contain a fluorescent substance detectable at different fluorescence wavelengths. Based on the fact that multiple nucleic acid probes are each bound to a fluorescent substance detectable at different fluorescence wavelengths, each different target nucleic acid sequence can be detected at different fluorescence wavelengths. The multiple different target nucleic acid sequences can be multiple different sequences from the same virus, viroid, or organism, or sequences derived from different viruses, viroids, or organisms.

[0183] 1-4. Effects

[0184] The nucleic acid probes of this invention do not bind to nucleic acid recombination-associated enzymes to form complexes, or their binding efficiency is low. Therefore, unlike the nucleic acid probes used in existing real-time detection methods based on RPA, fluorescent and quenching substances do not need to be introduced into the internal location of the nucleic acid probe. For example, even if fluorescent and / or quenching substances are introduced into the 5' and / or 3' ends of the nucleic acid probe, the quenching effect based on the quenching substances will not be lost due to the nucleic acid recombination-associated enzymes.

[0185] In existing real-time detection methods based on RPA, fluorescent and quenching substances are typically introduced into the thymine bases within the nucleic acid probe. However, this approach suffers from low freedom in selecting the base sequence constituting the nucleic acid probe, as well as high internal modification costs. In contrast, the nucleic acid probe of this invention, based on the aforementioned features, also allows for the introduction of fluorescent and / or quenching substances into the probe's terminal portion, thus enabling highly flexible design and avoiding the high costs associated with internal modification.

[0186] Furthermore, existing real-time detection methods based on RPA require nucleic acid probes with a length of approximately 30 to 60 meters to serve as substrates for nucleic acid recombination-related enzymes. This leads to problems such as the easy formation of dimers resulting in non-specific amplification, and the easy binding of primers and probes to each other in multiplex analyses, also causing non-specific amplification. In contrast, the nucleic acid probes of this invention allow for a length of less than 30 meters, thus avoiding the problem of non-specific amplification and enabling low-cost, high-throughput multiplex analysis.

[0187] According to the present invention, nucleic acid probes for detecting the target nucleic acid sequences described herein are also provided. Furthermore, target nucleic acid sequence detection reagents composed of the nucleic acid probes of the present invention are also provided.

[0188] 2. Methods for detecting target nucleic acid sequences

[0189] 2-1. Overview

[0190] The second aspect of the present invention is a method for detecting a target nucleic acid sequence (hereinafter sometimes simply referred to as the "detection method"). This detection method uses the nucleic acid probe, the first nucleic acid primer, and the second nucleic acid primer described in the first aspect to amplify the target nucleic acid sequence in the sample, while simultaneously inducing the cleavage of the nucleic acid probe based on the amplified target nucleic acid sequence, and detecting the fluorescence emitted by a fluorescent substance.

[0191] 2-2. Methods

[0192] The detection method of the present invention includes an amplification step and a detection step as necessary steps, and includes a reverse transcription step and an extraction step as optional steps. The following is a detailed description of each step in the method of this invention.

[0193] (Expansion process)

[0194] In this method, the "amplification step" refers to the step of amplifying the target nucleic acid sequence in the sample using any of the nucleic acid probes, the first nucleic acid primer, and the second nucleic acid primer described in the first method.

[0195] The nucleic acid amplification methods that can be used in this procedure are well-known in the art and can be performed according to the conditions described in the various experimental protocols. Examples of experimental protocols include the aforementioned Green, MR and Sambrook, J, (2012), Domingues L. (2017) PCR: Methods and Protocols, Methods in Molecular Biology, Humana Press, and Park DJ, (2010) PCR Protocols, Methods in Molecular Biology, Third Edition, Humana Press. Furthermore, nucleic acid amplification kits are commercially available from life science manufacturers and can also be used. In this case, the conditions for the nucleic acid amplification method can be performed according to the accompanying experimental protocol or the experimental protocol recommended by the respective manufacturer. In addition, to accelerate the nucleic acid amplification reaction, the reaction solution can be stirred, vortexed, and / or mixed before and / or during the reaction. There are no restrictions on the specific methods of stirring, vortexing, and / or mixing; for example, methods such as using a stirrer or vortex mixer, inverting to mix, pipetting, and tapping can be used. There are no restrictions on the number and frequency of stirring, shaking and / or mixing; for example, it can be carried out several to dozens of times during the reaction.

[0196] In one embodiment, the nucleic acid amplification method used in this process is isothermal nucleic acid amplification. Isothermal nucleic acid amplification methods may include, for example, RPA, SDA, EXPAR, or RCA.

[0197] The reaction conditions for nucleic acid amplification using isothermal nucleic acid amplification only need to be selected so that the polymerase used for amplification and the cleavage enzyme used to cut the cleavage site can function effectively. For example, under isothermal conditions above 20℃, 25℃, 30℃, 31℃, 32℃, 33℃, 34℃, 35℃, or 36℃, and / or below 65℃, 60℃, 55℃, 50℃, 47℃, 45℃, 43℃, 42℃, 41℃, 40℃, 39℃, 38℃, or 37℃, the reaction time can be 30 seconds to 3 hours, 1 minute to 2 hours, 5 minutes to 60 minutes, 10 minutes to 50 minutes, 15 minutes to 45 minutes, 20 minutes to 40 minutes, or 25 minutes to 35 minutes.

[0198] In one embodiment, this step uses a strand substitution DNA polymerase for amplification. Examples of strand substitution DNA polymerases include E. coli DNA polymerase I large fragment, Tli DNA polymerase, T7 DNA polymerase, T5 DNA polymerase, Phi29 DNA polymerase, Bsu DNA polymerase, Bsu DNA polymerase large fragment, Bst DNA polymerase, and Bst DNA polymerase large fragment. Commercially available products can also be used. Examples of commercially available products include Bsu DNA Polymerase, Large Fragment (manufactured by New England Biolabs), Bst DNA Polymerase (manufactured by Gene Co., Ltd., Japan), Bst 2.0 DNA Polymerase (manufactured by New England Biolabs), Bst2.0 WarmStart DNA Polymerase (manufactured by New England Biolabs), and Bst 3.0 DNA Polymerase (manufactured by New England Biolabs).

[0199] In one embodiment, this step involves amplification in the presence of nucleic acid recombination-related enzymes and cleavage enzymes (e.g., exonuclease III, ribonuclease H, DNA glycosylation enzyme, or endonuclease IV). The specific type of cleavage enzyme can be appropriately selected based on the type of cleavage site contained in the nucleic acid probe, as described above. For example, when the cleavage site is a debasing site, the cleavage enzyme is exonuclease III or endonuclease IV; when the cleavage site is a native ribonucleotide, the cleavage enzyme is ribonuclease H. On the other hand, when the cleavage site is an oxidized base, it can be a DNA glycosylation enzyme, exonuclease III, and / or endonuclease IV. This is because oxidized bases can be removed by DNA glycosylation enzymes to become debasing sites, which can be cleaved by DNA glycosylation enzymes, exonuclease III, or endonuclease IV. Commercially available products can also be used as the cleavage enzyme. Commercially available products include, for example, Exonuclease III (manufactured by Takara Bio Co., Ltd.), Endonuclease IV (manufactured by New England Biolabs), and Fpg (manufactured by New England Biolabs).

[0200] In one embodiment, this step may add components required for the amplification or cleavage reaction, such as dNTPs, ATP, DTT, congestants, buffers, reverse transcriptase, and additives, to the reaction solution. Furthermore, creatine kinase and phosphocreatine, or pyruvate kinase and phosphoenolpyruvate, may be added as an ATP regeneration system. Additionally, to prevent cross-contamination of amplification products, uracil DNA glycosylase (UNG) may be added to the reaction solution. In this case, dNTPs are replaced with dUTPs.

[0201] The sample supplied for this process can be any sample containing the target nucleic acid sequence. It can be a purified sample containing purified nucleic acid or an unpurified sample containing unpurified nucleic acid. The purified sample can also be a crude extract obtained by crude extraction using heat, alkali, surfactants, etc.

[0202] (Inspection process)

[0203] In this method, the "detection step" refers to the step of irradiating the nucleic acid probe with excitation light and detecting the fluorescence emitted by the fluorescent substance.

[0204] The wavelength of the excitation light used in this step can be appropriately selected based on the type of fluorescent substance bound to the nucleic acid probe. Similarly, the fluorescence wavelength used for fluorescence detection in this step can also be appropriately selected based on the type of fluorescent substance.

[0205] This step can be performed simultaneously with the amplification step described above, or it can be performed after the amplification step. When the detection step is performed during the amplification step, this step can be performed at certain time intervals, such as every 5 seconds, 10 seconds, 20 seconds, 30 seconds, 1 minute, 2 minutes, 5 minutes, or 10 minutes, thereby enabling the amplification process to be measured over time.

[0206] (Reverse transcription process)

[0207] In this method, the "reverse transcription step" refers to the process of reverse transcribing RNA before and / or during the amplification step when the target nucleic acid sequence is RNA. The reverse transcription step is a process of generating reverse transcription products (cDNA) using sample-derived RNA as a template, and using reverse transcription primers such as oligo-dT primers and enzymes such as reverse transcription polymerase.

[0208] The reverse transcription method used in this procedure can be any method known in the art. For example, it can be performed according to the reverse transcription method described in Green & Sambrook, Molecular Cloning, 2012, Fourth Ed., Cold Spring Harbor Laboratory Press. Furthermore, to accelerate the reverse transcription reaction, the reaction solution can be stirred, vortexed, and / or mixed before and / or during the reaction. There are no restrictions on the specific methods of stirring, vortexing, and / or mixing; examples include using a stirrer or vortex mixer, inverting to mix, pipetting, and tapping. There are also no restrictions on the number and frequency of stirring, vortexing, and / or mixing; for example, it can be performed several to dozens of times during the reaction.

[0209] (Extraction process)

[0210] In this method, the "extraction step" refers to the step of extracting nucleic acid containing the target nucleic acid sequence from the sample before the amplification step described above.

[0211] The method for extracting nucleic acids such as DNA in this process can be a conventional method known in the art. For example, it can be prepared according to the method described in Green & Sambrook, 2012, Molecular Cloning: A Laboratory Manual Fourth Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. Alternatively, commercially available DNA extraction kits can be used. Examples of commercially available DNA extraction kits include the Kaneka Simple DNA Extraction Kit version 2 (manufactured by Kaneka Corporation), the QIA prep SpinMiniprep Kit (manufactured by QIAGEN Corporation), and the ISOSPIN Tissue DNA (manufactured by Nippon Gene Corporation).

[0212] When this method includes the reverse transcription step described above, this extraction step extracts RNA from the sample. There are no particular limitations on the method for extracting RNA from the sample. For example, the conventional acid phenol method (Acid Guanidinium-Phenol-Chloroform (AGPC) method) can be used, or RNA extraction reagents containing acid phenol can be used. Examples of RNA extraction reagents that can be used in this step include TRIzol (Life Technologies) and Isogen (NipponGene Corporation). RNA extraction kits are commercially available from life science manufacturers such as Qiagen, Takara Bio, TOYOBO, Thermo Fisher Scientific, and Promega, and these kits can also be used.

[0213] In this approach or the first approach, the target nucleic acid sequence may be derived from a virus, a virus-like organism, and / or an organism.

[0214] The term "virus" in this instruction manual is not specifically limited and can refer to any type of DNA virus or RNA virus. Examples of DNA viruses include the Poxviridae family (e.g., smallpox virus), the Herpesviridae family (e.g., herpes simplex virus, Epstein-Barr virus, and varicella-zoster virus), the Baculoviridae family, the Parvoviridae family, the Adenoviridae family, the Papillomaviridae family (e.g., human papillomavirus), and the Hepatic Deoxyribonucleoviridae family (e.g., hepatitis B virus). Examples of RNA viruses include the Retroviridae family (e.g., human T-cell leukemia virus type 1 and human immunodeficiency virus), the Clonorviridae family, the Coronaviridae family (e.g., SARS-CoV and SARS-CoV-2), the Flaviviridae family (e.g., dengue virus, yellow fever virus, and hepatitis C virus), the Paramyxoviridae family (e.g., measles virus and mumps virus), the Orthomyxoviridae family (e.g., influenza virus), the Bunyaviridae family, the Caliciviridae family (e.g., norovirus), the Filoviridae family (e.g., Ebola virus), the Marshalliviridae family (e.g., rubella virus), the Picornaviridae family (e.g., poliovirus), and the Rhabdoviridae family (e.g., rabies virus).

[0215] The term "virus viroid" in this instruction manual is not particularly limited. Examples of viruses include those from the genera Avsunviroid (e.g., avocado sunblotch viroid), Parvemovirus (e.g., chrysanthemum chlorotic spot viroid), Pospiviroid (e.g., potato spindle tuber viroid), and Apscaviroid (e.g., apple wrinkled fruit viroid).

[0216] The term "organism" in this instruction manual is not particularly limited. For example, it can refer to single-celled organisms such as bacteria, fungi, and archaea, or multicellular organisms such as protists, plants, and animals. In addition, an organism can refer to pathogens such as infectious agents. Examples of bacteria that belong to the pathogenic bacteria category include Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, Neisseria meningitidis, Staphylococcus aureus, Streptococcus pyogenes (group A beta-hemolytic streptococci), Streptococcus pneumoniae, Shigella dysenteriae, Salmonella enterica, Vibrio cholerae, Pseudomonas aeruginosa, Bordetella pertussis, Mycobacterium tuberculosis, Corynebacterium diphtheriae, and Mycoplasma pneumoniae. Examples of pathogens include pneumoniae, Japanese spotted fever Rickettsia, and Salmonella enterica serovar Typhi.

[0217] In one embodiment, the method of this approach can be either single detection or multiplex detection. For example, in multiplex detection, multiple probe / primer sets can be used in the amplification and detection steps to amplify and detect multiple different target nucleic acid sequences. Since the nucleic acid probes in the multiple probe / primer sets used for multiplex detection each contain fluorescent substances detectable at different fluorescence wavelengths, different target nucleic acid sequences can be detected at different fluorescence wavelengths.

[0218] 2-3. Effects

[0219] In the detection method of the present invention, the available nucleic acid probes offer a high degree of freedom, and target nucleic acid sequences can be detected at low cost. Furthermore, the detection method of the present invention involves minimal non-specific amplification. Moreover, the detection method according to the present invention also enables low-cost and high-throughput multiplex analysis.

[0220] Furthermore, by applying the detection method of the present invention to samples obtained from test subjects, diseases related to the target nucleic acid sequence (e.g., infections caused by pathogens derived from the target nucleic acid sequence) can be diagnosed or assisted in the diagnosis. When the target nucleic acid sequence is detected through the detection process of this method, it indicates that the test subject, as the sample source, suffers from a disease related to the target nucleic acid sequence. For example, when a target nucleic acid sequence derived from SARS-CoV virus or SARS-CoV-2 virus is detected by the detection method of the present invention, it indicates that the test subject is infected with SARS-CoV and SARS-CoV2, respectively. Furthermore, when a target nucleic acid sequence derived from Neisseria gonorrhoeae or Chlamydia trachomatis is detected by the detection method of the present invention, it indicates that the test subject is infected with Neisseria gonorrhoeae or Chlamydia trachomatis, respectively.

[0221] Example

[0222] The present invention will now be described in detail with reference to embodiments. It should be noted that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention.

[0223] <Example 1: Probe Preparation>

[0224] (Purpose)

[0225] In existing real-time detection methods based on RPA, the internal modification of fluorescent and quenching substances is limited by thymine residues. This not only results in the inability to freely design probes but also in the high cost of introducing internal modifications. Furthermore, as mentioned above, since probes need to be approximately 30-60 meters long to become substrates for nucleic acid recombination-related enzymes, there is a tendency for dimer formation leading to non-specific amplification, and in the formation of multiplex systems, primers and probes can easily bind to each other, also resulting in non-specific amplification.

[0226] To address the aforementioned issues, this study focuses on the fact that, during polymerase-based extension reactions in the RPA method, the complementary strand to the template strand becomes a single strand, and considers the possibility that the probe can bind to this single-stranded region in a manner independent of nucleic acid recombination-related enzymes. Figure 3 Therefore, in this embodiment, a novel probe containing non-natural nucleotides is prepared that does not bind to nucleic acid recombination-related enzymes to form a complex.

[0227] (Methods and Results)

[0228] Using the S gene of SARS-CoV-2 as the detection target, the probes shown in Table 1 below were prepared.

[0229] [Table 1]

[0230]

[0231] S-probe 1, S-probe 2, and S-probe 3 are probes consisting of 4 LNA nucleotides, 1 abase site, and 7 DNA nucleotides (12 bases in total length), with fluorescent material (FAM) and quencher (BHQ1) binding to the 5' and 3' ends, respectively. The abase site is located at different positions in each of the three probes. S-probe 4 is a probe consisting of 10 LNA nucleotides, 1 abase site, and 7 DNA nucleotides (18 bases in total length), with fluorescent material (FAM) and quencher (BHQ1) binding to the 5' and 3' ends, respectively.

[0232] <Example 2: Study on the positional relationship between probe and primer>

[0233] (Purpose)

[0234] In the RPA method, during the polymerase-based extension reaction, the strand complementary to the template strand becomes a single strand. To investigate the appropriate positional relationship between the probe and primers required for the probe to bind to this single-stranded region and cleave the debasement site in the probe, real-time detection was performed using the probe prepared in Example 1 and primers designed for various positions of the probe for nucleic acid amplification.

[0235] (Methods and Results)

[0236] In this embodiment, the S gene of SARS-CoV-2 is used as the target for real-time detection. As the probe for real-time detection, the S-probe 1 prepared in Example 1 is used as the primer for nucleic acid amplification. A forward primer composed of the base sequence shown in sequence number 5 and various reverse primers composed of the base sequences shown in sequences 6 to 12 are used. The 3' terminal bases of the reverse primers composed of the base sequences shown in sequences 6 to 12 correspond to the positions of 0, +1, +3, +5, +10, +20, and +43 bases, based on the position of the base adjacent to the 3' terminal base of the probe (the direction of the probe's 3' terminal is indicated as the forward direction).

[0237] In the amplification reaction solution, a synthetic DNA fragment (20,000 copies / reaction solution) consisting of a base sequence (sequence number 13) derived from the S gene in the SARS-CoV-2 genome was added as template DNA. 420 nM forward and reverse primers were added as amplification primers, and 120 nM S-probe 1 was added as a detection probe. Subsequently, 5 U of Bsu DNA polymerase fragment (manufacturer: New England Biolabs, model M0330S), 100 U of exonuclease III (manufacturer: Takara Bio, model 2170A), 160 ng / μL of UvsX recombinase (manufacturer: IntactGenomics, model 3562), 40 ng / μL of UvsY accessory protein (manufacturer: Intact Genomics, model 3572), and 700 ng / μL of gp32 protein (single-strand binding protein; SSB) (manufacturer: Nippon Gene, model 312-03251), along with necessary components such as dNTPs, ATP, creatine phosphate, and creatine kinase, were added to the reaction solution. Real-time detection was performed using a LightCycler 96 System and the reaction was carried out at 45°C for 40 minutes. Fluorescence was detected every 30 seconds.

[0238] Real-time detection results are shown in Figure 6 When the 3' terminal base of the reverse primer is located at positions of 0, +1, +3, +5, +10, +20, and +43, based on the position of the base adjacent to the 3' terminal base of the probe, it can efficiently detect template nucleic acids.

[0239] To analyze the positional relationship between the probes and primers that can detect template nucleic acids in more detail, S-probe 1, S-probe 2, S-probe 3, and S-probe 4 prepared in Example 1 were combined with various reverse primers, and real-time detection was performed using the same method as described above. Specifically, S-probe 1 was combined with the reverse primer shown in sequence number 14 ( Figure 7 Combination #1), S-probe 1 and the reverse primer shown in sequence number 15 ( Figure 7 Combination #2), S-probe 2 and the reverse primer shown in sequence number 16 ( Figure 7 Combination #3), S-probe 3 and the reverse primer shown in sequence number 17 ( Figure 7 Combination #4), S-probe 1 and the reverse primer shown in sequence number 16 ( Figure 7 Combination #5), S-probe 2 and the reverse primer shown in sequence number 18 ( Figure 7 Combination #6), S-probe 4 and the reverse primer shown in sequence number 16 ( Figure 7Combination #7), S-probe 1 and the reverse primer shown in sequence number 19 ( Figure 7 Combination #8), S-probe 3 and the reverse primer shown in sequence number 16 ( Figure 7 Combination #9), S-probe 3 and the reverse primer shown in sequence number 19 ( Figure 7 Combination #10) or S-probe 3 with the reverse primer shown in sequence number 18 ( Figure 7 Combinations #11 and #2 were combined and real-time detection was performed using a common forward primer consisting of the base sequence shown in sequence number 5. The lengths of the 3' end overlap region and the 5' end overlap region in each combination are within the range of... Figure 7 The results, denoted as "A" and "B" respectively, indicate whether the substance can be detected. Figure 7 In the right column of the table. It should be noted that in this embodiment, the overlapping region within the probe-binding region is less than 85% of the total length of the probe-binding region. Based on this result, it was found that if the probe and primer are positioned in overlapping regions, and the 3' end overlapping region ("A") is less than 3 bases and the 5' end overlapping region ("B") is more than 0 bases, or the 3' end overlapping region ("A") is 4 to 6 bases and the 5' end overlapping region ("B") is less than 4 bases, then real-time detection of the target sequence can be achieved. Furthermore, it was found that by making the overlapping region within the probe-binding region less than 85% of the total length of the probe-binding region, real-time detection of the target sequence can be achieved.

[0240] <Example 3: Comparison with Existing Real-Time Detection Methods>

[0241] (Purpose)

[0242] As described above, existing real-time detection methods based on RPA use probes longer than 30 meters that are bound to fluorescent and quenching substances within the nucleic acid strand rather than at both ends. In this embodiment, the probe of the present invention prepared in Example 1 is compared with a probe designed according to existing methods for specificity, detection limit, etc.

[0243] (Methods and Results)

[0244] (1) Preparation of probes based on existing methods

[0245] To compare probes based on existing methods as control probes, the probes shown in Table 2 below were prepared.

[0246] [Table 2]

[0247]

[0248] S-Probe 5 is a probe that targets the S gene of SARS-CoV-2. It has two deoxyribonucleotides containing thymine bases that bind fluorescent or quenching substances inside the probe, with debasement sites between the thymine bases. The probe is 56 bases long, including the debasement sites.

[0249] (2) Comparison of specificity

[0250] To compare the specificity of probe S-probe 1 of the present invention with probe S-probe 5 based on a prior art method, amplification was performed using the RPA method as follows. When using probe S-probe 1 of the present invention, a primer pair consisting of a forward primer with the base sequence shown in Serial No. 5 and a reverse primer shown in Serial No. 14 was used. When using probe S-probe 5 based on a prior art method, a primer pair consisting of a forward primer with the base sequence shown in Serial No. 5 and a reverse primer shown in Serial No. 12 was used. For each probe, experiments were conducted with and without template DNA, using a synthetic DNA fragment (20,000 copies / reaction solution) consisting of a base sequence derived from the S gene in the SARS-CoV-2 genome (Serial No. 13). Reactions were carried out for 40 minutes at 25°C, 37°C, 39.5°C, 40°C, 43°C, or 45°C. Reaction conditions other than those described above were performed according to Example 2.

[0251] The specificity comparison results are shown in Figure 8 When using existing real-time detection methods, under any temperature condition, the fluorescence signal increases not only in the case of template DNA addition (“template (+)” in the figure) but also in the case of no template DNA addition (“template (−)” in the figure). Figure 8 (A) In contrast, in the real-time detection method of the present invention, under any temperature condition, an increase in fluorescence signal was observed only under the condition of adding template DNA ("template (+)" in the figure), while no increase in fluorescence signal was observed under the condition of not adding template DNA ("template (−)" in the figure). Figure 8 (B in the original text). Based on this result, the real-time detection method of the present invention has higher specificity compared to existing real-time detection methods.

[0252] (3) Comparison of detection limits for template DNA

[0253] To compare the detection limits against template DNA of the present invention's probe S-probe 1 and the probe S-probe 5 based on existing methods, amplification was performed using the RPA method as follows. For each probe, the reaction was carried out under the following conditions: 2 copies / reaction solution, 20 copies / reaction solution, 200 copies / reaction solution, 2000 copies / reaction solution, 20000 copies / reaction solution, or 200000 copies / reaction solution were added as template DNA, and no template DNA was added. The same primer pairs as described in (2) were used for each probe in the amplification reaction, and the reaction temperature was 37°C when using the probe based on existing methods and 45°C when using the probe of the present invention. Other reaction conditions were as described in Example 2.

[0254] The comparison results of the detection limits are shown in Figure 9 The detection limit of existing probes (control probes) is 20 copies / reaction solution to 200 copies / reaction solution, while the detection limit of the probe of this invention is less than 20 copies / reaction solution, and it can detect 20 copies of template within 15 minutes. This result indicates that the real-time detection method of this invention reduces the detection limit for template DNA by more than 10 times compared to existing real-time detection methods.

[0255] (4) Comparison of detection limits for template RNA

[0256] To compare the detection limits of probe S-probe 1 of the present invention and probe S-probe 5 based on existing methods against template RNA, amplification was performed using the RPA method as follows. For each probe, the reaction was carried out under conditions where synthetic RNA consisting of a base sequence derived from the S gene in the SARS-CoV-2 genome (sequence number 36; in the sequence "T" represents "U") was added as template RNA to achieve 2 copies / reaction solution, 20 copies / reaction solution, 200 copies / reaction solution, 2000 copies / reaction solution, or 20000 copies / reaction solution, and without the addition of template DNA. 420 nM forward and reverse primers were used as amplification primers, and 120 nM S-probe 1 or S-probe 5 was used as the detection probe. The Bsu DNA polymerase fragment, exonuclease III, UvsX recombinase, UvsY auxiliary protein, gp32 protein, and 200 U of M-MVL reverse transcriptase (manufacturer: Nippon Gene Co., Ltd., model 313-08161) at the concentrations shown in Example 2 were added to the reaction solution along with necessary components such as dNTPs, ATP, creatine phosphate, and creatine kinase. The same primer pairs as described in (2) were used for detection by each probe, and the amplification reaction was carried out at 45°C for 40 minutes.

[0257] The amplification results are shown in Figure 10 The detection limit of probes based on existing methods is 20 copies / reaction solution to 200 copies / reaction solution, while the detection limit of the probe of this invention is 2 copies / reaction solution to 20 copies / reaction solution, and the probe of this invention can detect 200 copies of template RNA within 20 minutes. This result indicates that the real-time detection method of this invention reduces the detection limit for template RNA by approximately 10 times compared to existing real-time detection methods.

[0258] <Example 4: Real-time detection in the impurity system>

[0259] (Purpose)

[0260] Real-time detection is performed based on the RPA method in the presence of various impurities.

[0261] (Methods and Results)

[0262] Using the probe S-probe 1 of this invention, real-time detection based on the RPA method was performed according to the following method. Amplification reactions were performed with and without impurities, respectively, under conditions where a synthetic DNA fragment consisting of a base sequence derived from the SARS-CoV-2 genome S gene (Sequence No. 13) was added as template DNA to reach 2000 copies / reaction solution, and under conditions where no template DNA was added. As impurities, human genomic DNA (20 ng / reaction solution) or saliva-derived DNA extract (5 μL / reaction solution) was used. The saliva-derived DNA extract was prepared by adding 100 μL of Kaneka Simple DNA Extraction Kit version 2 reagent A to 20 μL of saliva collected from a human body, heating at 98°C for 10 minutes, adding 14 μL of reagent B, and suspending. As primers for amplification, a primer pair consisting of a forward primer consisting of the base sequence shown in Sequence No. 5 and a reverse primer shown in Sequence No. 14 was used, and the reaction temperature was 45°C. Reaction conditions other than those described above were as described in Example 2.

[0263] Real-time detection results are shown in Figure 11 The results showed that, even in the presence of any impurity, the template DNA with 2000 copies could be fully detected using the probe S-probe 1 of this invention.

[0264] <Example 5: Detection of Chlamydia trachomatis and Neisseria gonorrhoeae>

[0265] (Purpose)

[0266] Real-time detection is carried out using DNA derived from Chlamydia trachomatis and Neisseria gonorrhoeae.

[0267] (Methods and Results)

[0268] (1) Probe fabrication

[0269] The probes shown in Table 3 below were prepared using the ORF4 sequence of plasmid DNA derived from Chlamydia trachomatis and the porA gene sequence derived from Neisseria gonorrhoeae as detection targets.

[0270] [Table 3]

[0271]

[0272] CTP-probe 1 targets the ORF4 sequence of plasmid DNA derived from *Chlamydia trachomatis*, and consists of 8 LNA nucleotides, 1 abase site, and 6 DNA nucleotides (15 bases in total). The fluorescent agent (FAM) and quencher (BHQ1) bind to the 5' and 3' ends, respectively. CTP-probe 2 (15 bases in total) differs from CTP-probe 1 in that ROX is used instead of FAM as the fluorescent agent. NG-probe 1 targets the porA gene sequence derived from *Neisseria gonorrhoeae*, and consists of 8 LNA nucleotides, 1 abase site, and 6 DNA nucleotides (15 bases in total). The fluorescent agent (FAM) and quencher (BHQ1) bind to the 5' and 3' ends, respectively.

[0273] (2) Single detection

[0274] Using the ORF4 sequence of plasmid DNA from *Chlamydia trachomatis* and the porA gene from *Neisseria gonorrhoeae* as detection targets, amplification was performed using the RPA method as follows. When using the ORF4 sequence of plasmid DNA from *Chlamydia trachomatis* as the detection target, the CTP-probe 1 shown in Table 3 above was combined with various reverse primers for amplification. Specifically, CTP-probe 1 was combined with the reverse primer shown in sequence number 25 (… Figure 12 Combination #12), CTP-probe 1 and the reverse primer shown in sequence number 26 ( Figure 12 Combination #13), CTP-probe 1 and the reverse primer shown in sequence number 27 ( Figure 12 Combination #14), CTP-probe 1 and the reverse primer shown in sequence number 28 ( Figure 12Combination #15) was used, and a common forward primer consisting of the base sequence shown in sequence number 24 was used. Amplification reactions were performed under the following conditions: with the addition of a synthetic DNA fragment consisting of the ORF4 base sequence (sequence number 29) of plasmid DNA derived from Chlamydia trachomatis (20,000 copies / reaction solution) as template DNA, and without the addition of template DNA. When the porA gene derived from Neisseria gonorrhoeae was used as the detection target, the NG-probe 1 shown in Table 3 above was combined with various reverse primers for amplification reactions. Specifically, the NG-probe 1 was combined with the reverse primer shown in sequence number 31 ( Figure 12 Combination #16), NG-probe 1 and the reverse primer shown in sequence number 32 ( Figure 12 Combination #17), NG-probe 1 and the reverse primer shown in sequence number 33 ( Figure 12 Combination #18), NG-probe 1 and the reverse primer shown in sequence number 34 ( Figure 12 The reaction was performed using a common forward primer consisting of the base sequence shown in sequence number 30, with and without the addition of a synthetic DNA fragment (20,000 copies / reaction solution) consisting of the porA gene base sequence (sequence number 36) from Neisseria gonorrhoeae as template DNA. The reaction was carried out at 45°C for 40 minutes. All other reaction conditions were as described in Example 2.

[0275] The lengths of the 3' and 5' end overlap regions in each probe-reverse primer combination are shown as "A" and "B" respectively, in the same manner as in Example 2. Figure 12 The real-time detection results are shown in the table. Figure 12 .Depend on Figure 12 A and Figure 12 As shown in result B, any object can be detected using the probe of this invention.

[0276] (3) Multiple detection

[0277] The presence of each sequence was detected in real time using different fluorescence wavelengths from the same sample containing nucleic acids with plasmid DNA sequences derived from Chlamydia trachomatis and nucleic acids with porA gene sequences derived from Neisseria gonorrhoeae. Specifically, under the following conditions: adding only Vircell's Chlamydia trachomatis DNA control (AMPLIRUN, registered trademark) (2000 copies / reaction solution) as template DNA; adding only Vircell's Neisseria gonorrhoeae DNA control (AMPLIRUN, registered trademark) (2000 copies / reaction solution) as template DNA; adding both Chlamydia trachomatis and Neisseria gonorrhoeae DNA control as template DNA; and not adding any template DNA, CTP-probe 2 and NG-probe 1 as shown in Table 3 above were used, along with primer pairs (sequence numbers 24 and 27) for amplifying plasmid DNA sequences derived from Chlamydia trachomatis and primer pairs (sequence numbers 30 and 33) for amplifying the porA gene sequence derived from Neisseria gonorrhoeae, and the reaction was carried out at 45°C for 40 minutes. The plasmid DNA sequence derived from *Chlamydia trachomatis* was detected under 599 nm fluorescence from ROX, and the porA gene sequence derived from *Neisseria gonorrhoeae* was detected under 520 nm fluorescence from FAM. Reaction conditions other than those described above were as described in Example 2.

[0278] Multiple real-time detection results are shown Figure 13 .according to Figure 13 A and Figure 14 The results shown in B indicate that the target nucleic acid sequences can be detected simultaneously in real time from samples containing only nucleic acids with ORF4 sequences of plasmid DNA from Chlamydia trachomatis, samples containing only nucleic acids with porA gene sequences from Neisseria gonorrhoeae, and samples containing both nucleic acids with ORF4 sequences of plasmid DNA from Chlamydia trachomatis and nucleic acids with porA gene sequences from Neisseria gonorrhoeae.

[0279] <Example 6: Detection of the S gene of SARS-CoV-2 using an AmNA-containing probe>

[0280] (Purpose)

[0281] In the S-probe 1 prepared in Example 1, all or part of the LNA nucleotides were replaced with AmNA nucleotides to prepare the probe, and the S gene of SARS-CoV-2 was used as the detection target for real-time detection.

[0282] (Methods and Results)

[0283] (1) Probe fabrication

[0284] The probes shown in Table 4 below were prepared by replacing all or part of the LNA nucleotides with AmNA nucleotides in the S-probe 1 prepared in Example 1.

[0285] [Table 4]

[0286]

[0287] S-probe 1, S-probe 23, and S-probe 24 are probes that use the S gene of SARS-CoV-2 as a target for real-time detection. They consist of 4 non-natural nucleotides, 1 abase site, and 7 DNA nucleotides (12 bases in total length), with fluorescent material (FAM) and quencher (BHQ1) binding to the 5' and 3' ends, respectively. The composition of the non-natural nucleotides differs among the three probes. S-probe 1 contains 4 LNA nucleotides. S-probe 23 contains 4 AmNA nucleotides. S-probe 24 contains 2 LNA nucleotides and 2 AmNA nucleotides.

[0288] (2) Evaluation of the cutting efficiency of the probe

[0289] Double-stranded DNA was prepared by adding DNA oligonucleotides (Sequence No. 43) with sequences complementary to S-probe 1, S-probe 23, and S-probe 24, respectively. 2 U of exonuclease III was added to 120 nM of the double-stranded DNA, and the mixture was reacted at 37°C for 5 minutes. Fluorescence was measured before and after the reaction. The fluorescence intensity in the solution without exonuclease III was set as 1, and the relative fluorescence intensity was calculated based on the fluorescence intensity in the solution containing exonuclease III.

[0290] The relative fluorescence intensity of solutions containing exonuclease III compared to solutions without exonuclease III was calculated. The results showed that S-probe 1 was 3.1, S-probe 23 was 3.7, and S-probe 24 was 3.8. The increase in fluorescence intensity after the addition of exonuclease III indicates that all probes were cleaved by exonuclease III. Furthermore, the cleavage efficiency of probes containing a combination of AmNA and LNA nucleotides was more than 20% higher than that of probes containing only LNA nucleotides as non-natural nucleotides.

[0291] (3) Real-time detection

[0292] In real-time detection, in addition to the probes prepared as described in (1), a forward primer composed of the base sequence shown in sequence number 5 and a reverse primer composed of the base sequence shown in sequence number 16 were used as primers for nucleic acid amplification. In the amplification reaction solution, a synthetic DNA fragment (20 or 200 copies / reaction solution) composed of the base sequence derived from the S gene in the SARS-CoV-2 genome (sequence number 13) was added as template DNA. 420 nM of forward and reverse primers were added as amplification primers, and 120 nM of S-probe 1, S-probe 23, or S-probe 24 were added as detection probes. Amplification was performed at 45°C for 15 minutes while stirring the reaction solution. The reaction conditions, except as described above, followed those in Example 2. Furthermore, based on the obtained amplification curve, the crossover time (in minutes) between the threshold and the amplification curve was calculated: Tt (threshold time).

[0293] 200 copies of template DNA per reaction solution were added to the reaction solution and real-time detection was performed. The results are as follows: Figure 14 As shown in A in the figure. The Tt values ​​of different probes were calculated, and the results were: S-probe 1 = 8.2, S-probe 23 = 5.4, and S-probe 24 = 4.7.

[0294] In addition, template DNA at a concentration of 20 copies per reaction solution was added to the reaction solution and real-time detection was performed, with results as follows: Figure 14 As shown in B in the figure. The Tt values ​​were calculated, and the results were: S-probe 17 = 9.4, S-probe 25 = 6.4, and S-probe 26 = 6.0.

[0295] Depend on Figure 14 The results show that, compared with probes containing only LNA nucleotides as non-natural nucleotides, probes containing only AmNA nucleotides as non-natural nucleotides, and probes containing a combination of AmNA and LNA nucleotides as non-natural nucleotides, can detect the S gene of the SARS-CoV-2 genome more quickly. Specifically, the Tt value was reduced by 30%–40%.

[0296] <Example 7: Detection of Chlamydia trachomatis using AmNA-containing probes>

[0297] (Purpose)

[0298] In the CTP-probe 1 prepared in Example 5, all or part of the LNA nucleotides were replaced with AmNA nucleotides to prepare the probe, and real-time detection was performed using DNA derived from Chlamydia trachomatis as the detection target.

[0299] (Methods and Results)

[0300] The probes shown in Table 5 below were prepared by replacing all or part of the LNA nucleotides with AmNA nucleotides in the CTP-probe 1 prepared in Example 5.

[0301] [Table 5]

[0302]

[0303] CTP-probe 1, CTP-probe 3, and CTP-probe 4 are probes that use DNA derived from Chlamydia trachomatis as the target for real-time detection. They consist of 8 non-natural nucleotides, 1 abase site, and 6–8 DNA nucleotides (15 or 17 bases in total length), with fluorescent material (FAM) and quencher (BHQ1) bound to the 5' and 3' ends, respectively. The composition of the non-natural nucleotides differs among the three probes. CTP-probe 1 contains 8 LNA nucleotides. CTP-probe 3 contains 8 AmNA nucleotides. CTP-probe 4 contains 3 LNA nucleotides and 5 AmNA nucleotides.

[0304] (2) Real-time detection

[0305] In real-time detection, in addition to the probe prepared as described in (1), a forward primer composed of the base sequence shown in sequence number 24 and a reverse primer composed of the base sequence shown in sequence number 27 were used as primers for nucleic acid amplification. In the amplification reaction solution, a synthetic DNA fragment (20, 200, or 2000 copies / reaction solution) composed of the ORF4 base sequence (sequence number 29) of plasmid DNA derived from Chlamydia trachomatis was added as template DNA, and 420 nM of forward and reverse primers were added as amplification primers, and 120 nM of CTP-probe 1, CTP-probe 3, or CTP-probe 4 were added as detection probes. The reaction solution was amplified at 45°C for 15 minutes. Other reaction conditions were as described in Example 2.

[0306] Real-time detection results such as Figure 15 As shown. By Figure 15 The results show that probes containing only AmNA nucleotides as non-natural nucleotides, and probes containing a combination of AmNA and LNA nucleotides as non-natural nucleotides, can detect DNA from Chlamydia trachomatis equally well as probes containing only LNA nucleotides as non-natural nucleotides.

[0307] <Example 8: Detection of Neisseria gonorrhoeae using AmNA-containing probes>

[0308] (Purpose)

[0309] In the NG-probe 1 prepared in Example 5, all or part of the LNA nucleotides were replaced with AmNA nucleotides to prepare the probe, and real-time detection was performed using DNA derived from Neisseria gonorrhoeae as the detection target.

[0310] (Methods and Results)

[0311] (1) Probe fabrication

[0312] The probes shown in Table 6 below were prepared by replacing all or part of the LNA nucleotides with AmNA nucleotides in the NG-probe 1 prepared in Example 5.

[0313] [Table 6]

[0314]

[0315] NG-probe 1, NG-probe 2, and NG-probe 3 are probes that use Neisseria gonorrhoeae DNA as a target for real-time detection. They consist of 8 non-natural nucleotides, 1 abase site, and 6 DNA nucleotides (15 bases in total length), with fluorescent material (FAM) and quencher (BHQ1) bound to the 5' and 3' ends, respectively. The composition of the non-natural nucleotides differs among the three probes. NG-probe 1 contains 8 LNA nucleotides. NG-probe 2 contains 8 AmNA nucleotides. NG-probe 3 contains 2 LNA nucleotides and 6 AmNA nucleotides.

[0316] (2) Real-time detection

[0317] In real-time detection, in addition to the probe prepared as described in (1), a forward primer consisting of the base sequence shown in sequence number 30 and a reverse primer consisting of the base sequence shown in sequence number 33 were used as primers for nucleic acid amplification. In the amplification reaction solution, a synthetic DNA fragment consisting of the porA gene base sequence (sequence number 36) derived from Neisseria gonorrhoeae (20, 200, or 2000 copies / reaction solution) was added as template DNA, and 420 nM of forward and reverse primers were added as amplification primers, and 120 nM of NG-probe 1, NG-probe 2, or NG-probe 3 were added as detection probes. The reaction solution was amplified at 45°C for 15 minutes. Other reaction conditions were as described in Example 2.

[0318] Real-time detection results such as Figure 16 As shown. By Figure 16 The results show that probes containing only AmNA nucleotides as non-natural nucleotides, and probes containing a combination of AmNA and LNA nucleotides as non-natural nucleotides, can detect DNA from Neisseria gonorrhoeae as effectively as probes containing only LNA nucleotides as non-natural nucleotides.

[0319] All publications, patents and patent applications referenced in this specification are incorporated herein by reference.

Claims

1. A composition or kit for detecting a target nucleic acid sequence, comprising a nucleic acid probe for detecting a target nucleic acid sequence or its complementary sequence, a first nucleic acid primer, and a second nucleic acid primer. The nucleic acid probe contains one or more abase sites, oxidized bases, or native ribonucleotides. In addition to the abase sites, it contains a base sequence complementary to the probe-binding region of the target nucleic acid sequence or its complementary sequence. It also contains a fluorescent substance and a quenching substance that bind to the nucleic acid probe, and contains one or more non-native nucleotides. Furthermore, it does not bind to nucleic acid recombination-related enzymes to form a complex. The first nucleic acid primer contains a base sequence complementary to the first primer-binding region located at the 3' end of the target nucleic acid sequence, and serves as a substrate for nucleic acid recombination-related enzymes. The second nucleic acid primer contains a base sequence complementary to the second primer binding region located at the 3' end of the complementary sequence of the target nucleic acid sequence, and serves as a substrate for nucleic acid recombination-related enzymes.

2. The composition or kit of claim 1, wherein, It contains a fluorescent substance that binds to the 5' or 3' end of the nucleic acid probe, and a quenching substance that binds to the other end.

3. The composition or kit of claim 1, wherein, The length of the nucleic acid probe is 10 to 20 bases.

4. The composition or kit of claim 1, wherein, The non-natural nucleotides are bridged nucleotides or 2'-modified nucleotides.

5. The composition or kit according to claim 4, wherein, The bridging nucleotide is an LNA nucleotide, an AmNA nucleotide, or a GuNA nucleotide.

6. The composition or kit according to claim 4, wherein, The bridging nucleotides comprise LNA nucleotides and AmNA nucleotides, or LNA nucleotides and GuNA nucleotides.

7. The composition or kit according to claim 1, wherein, The probe binding region is located within a gap region in the target nucleic acid sequence, which is the region other than the first primer binding region and the region consisting of a base sequence complementary to the second primer binding region.

8. The composition or kit according to claim 5, wherein, The probe binding region is located in the area 5' further to the end of the notch region than the center.

9. The composition or kit according to claim 1, wherein, The probe binding region is located within a gap region in the complementary sequence of the target nucleic acid sequence, and the gap region is the region other than the second primer binding region and the region composed of base sequences complementary to the first primer binding region.

10. The composition or kit according to claim 9, wherein, The probe binding region is located in the area 5' further to the end of the notch region than the center.

11. The composition or kit according to claim 1, wherein, The probe binding region comprises at least one base located on the 3' end side of a region in the target nucleic acid sequence consisting of base sequences complementary to the binding region of the second primer, and The region in the target nucleic acid sequence consisting of a base sequence complementary to the binding region of the second primer does not include the bases in the probe binding region corresponding to the abase site of the nucleic acid probe, or the bases complementary to the oxidized bases or the natural ribonucleotides.

12. The composition or kit according to claim 1, wherein, The region in the target nucleic acid sequence composed of base sequences complementary to the binding region of the second primer includes bases in the probe binding region corresponding to the abase site of the nucleic acid probe, or bases complementary to the oxidized base or the native ribonucleotide, and The debasement site, the oxidized base, or the natural ribonucleotide of the nucleic acid probe, in the presence of the second nucleic acid primer and in the absence of the target nucleic acid sequence, shall not be cleaved by exonuclease III, ribonuclease H, DNA glycosylase, or endonuclease IV.

13. The composition or kit according to claim 12, wherein, In the probe binding region, the overlapping region comprised of the base sequence complementary to the second primer binding region is less than 85% of the total length of the probe binding region.

14. The composition or kit according to claim 13, wherein, In the probe binding region, the length of the 3' end overlap region located further to the 3' end than the base corresponding to the ablation site of the nucleic acid probe, or the base complementary to the oxidized base or the natural ribonucleotide, and consisting of a base sequence complementary to the second primer binding region, is less than 3 bases.

15. The composition or kit according to claim 13, wherein, In the probe binding region, the length of the 3' end overlap region located further to the 3' end than the base corresponding to the ablation site of the nucleic acid probe, or the base complementary to the oxidized base or the native ribonucleotide, and consisting of a sequence of bases complementary to the second primer binding region, is 4 to 6 bases. In the probe binding region, the length of the 5' end overlap region located further to the 5' end than the base corresponding to the ablation site of the nucleic acid probe, or the base complementary to the oxidized base or the native ribonucleotide, is less than 4 bases.

16. The composition or kit according to claim 1, wherein, The probe binding region comprises at least one base on the 3' end side of a region in the complementary sequence of the target nucleic acid sequence consisting of bases complementary to the first primer binding region, and The region in the complementary sequence of the target nucleic acid sequence consisting of a base sequence complementary to the binding region of the first primer is not included in the bases in the probe binding region corresponding to the abase site of the nucleic acid probe, or bases complementary to the oxidized base or the natural ribonucleotide.

17. The composition or kit according to claim 1, wherein, The region in the complementary sequence of the target nucleic acid sequence consisting of base sequences complementary to the binding region of the first primer includes bases in the probe binding region corresponding to the abase site of the nucleic acid probe, or bases complementary to the oxidized base or the native ribonucleotide, and The debasement site, the oxidized base, or the natural ribonucleotide of the nucleic acid probe, in the presence of the first nucleic acid primer and in the absence of a complementary sequence to the target nucleic acid sequence, shall not be cleaved by exonuclease III, ribonuclease H, DNA glycosylase, or endonuclease IV.

18. The composition or kit according to claim 17, wherein, In the probe binding region, the overlapping region comprised of the base sequence complementary to the first primer binding region is less than 85% of the total length of the probe binding region.

19. The composition or kit according to claim 18, wherein, In the probe binding region, the length of the 3' end overlap region located further to the 3' end than the base corresponding to the ablation site of the nucleic acid probe, or the base complementary to the oxidized base or the natural ribonucleotide, and consisting of a base sequence complementary to the first primer binding region, is less than 3 bases.

20. The composition or kit according to claim 18, wherein, In the probe binding region, the length of the 3' end overlap region located further to the 3' end than the base corresponding to the ablation site of the nucleic acid probe, or the base complementary to the oxidized base or the native ribonucleotide, and consisting of a sequence of bases complementary to the first primer binding region, is 4 to 6 bases. In the probe binding region, the length of the 5' end overlap region located further to the 5' end than the base corresponding to the ablation site of the nucleic acid probe, or the base complementary to the oxidized base or the native ribonucleotide, is less than 4 bases.

21. The composition or kit according to claim 1, used for isothermal nucleic acid amplification.

22. The composition or kit according to claim 21, wherein, It further includes strand displacement DNA polymerase, exonuclease III, ribonuclease H, DNA glycosylation enzyme, endonuclease IV, and / or nucleic acid recombination-related enzymes.

23. A composition or kit for multiplex detection, comprising multiple probe / primer sets for detecting multiple different target nucleic acid sequences or their complementary sequences. Each probe / primer set comprises the nucleic acid probe of claim 1, a first nucleic acid primer, and a second nucleic acid primer. The nucleic acid probes in the plurality of probe / primer sets each contain a fluorescent substance that can be detected at different fluorescence wavelengths.

24. The composition or kit according to claim 23, wherein, The different target nucleic acid sequences are derived from the same or different viruses, viroids, and / or organisms.

25. A method for detecting a target nucleic acid sequence in a sample, comprising: The amplification process involves using the nucleic acid probe, the first nucleic acid primer, and the second nucleic acid primer as described in claim 1 to amplify the target nucleic acid sequence and / or its complementary sequence in the sample using a nucleic acid amplification method. as well as The detection process involves irradiating the nucleic acid probe during and / or after the amplification process with excitation light and detecting the fluorescence emitted by the fluorescent substance.

26. The method according to claim 25, wherein, The nucleic acid amplification method is the isothermal nucleic acid amplification method.

27. The method according to claim 26, wherein, The amplification process uses a strand displacement DNA polymerase.

28. The method according to claim 27, wherein, The amplification process is performed in the presence of nucleic acid recombination-related enzymes, as well as exonuclease III, ribonuclease H, DNA glycosylation enzyme, or endonuclease IV.

29. The method according to claim 25, wherein, The target nucleic acid sequence is composed of RNA, and further includes a reverse transcription process in which the RNA is reverse transcribed before and / or during the amplification process.

30. The method according to claim 25, wherein, Prior to the amplification step, an extraction step is further included to extract nucleic acid containing the target nucleic acid sequence from the sample.

31. The method according to claim 25, wherein, The sample is a cell, tissue, cell extract, tissue extract, tissue fluid, or body fluid.

32. The method according to claim 26, wherein, The target nucleic acid sequence is derived from viruses, viroids, and / or organisms.

33. A nucleic acid probe for detecting a target nucleic acid sequence, comprising one or more abase sites, oxidized bases, or native ribonucleotides. In addition to the aforementioned abase sites, it includes a base sequence complementary to the probe-binding region within the target nucleic acid sequence or its complementary sequence. It contains a fluorescent substance and a quenching substance that bind to the nucleic acid probe, and It contains one or more non-natural nucleotides and does not bind to nucleic acid recombination-related enzymes to form a complex.

34. The nucleic acid probe according to claim 33, wherein, It contains a fluorescent substance that binds to the 5' or 3' end of the nucleic acid probe, and a quenching substance that binds to the other end.

35. The nucleic acid probe according to claim 33, wherein the length is 10 to 20 bases.

36. The nucleic acid probe according to claim 33, wherein, The non-natural nucleotides are bridged nucleotides or 2'-modified nucleotides.

37. The nucleic acid probe according to claim 36, wherein, The bridging nucleotide is an LNA nucleotide, an AmNA nucleotide, or a GuNA nucleotide.

38. The nucleic acid probe according to claim 36, wherein, The bridging nucleotides comprise LNA nucleotides and AmNA nucleotides, or LNA nucleotides and GuNA nucleotides.

Citation Information

Patent Citations

  • Method for multiplexing recombinase polymerase amplification

    JP2009502161A

  • Electronic apparatus

    JP2024051145A